BioLargo (BLGO) 10-Q 14 Nov 24 2024 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2024	Nov. 12, 2024
Document Information [Line Items]
Entity Central Index Key	0000880242
Entity Registrant Name	BIOLARGO, INC.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2024
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2024
Document Transition Report	false
Entity File Number	000-19709
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	65-0159115
Entity Address, Address Line One	14921 Chestnut St.
Entity Address, City or Town	Westminster
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92683
City Area Code	888
Local Phone Number	400-2863
Title of 12(b) Security	Common stock
Trading Symbol	BLGO
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		301,179,163

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 3,882,000	$ 3,539,000
Accounts receivable, net of allowance	3,209,000	2,612,000
Inventories, net of allowance	238,000	153,000
Prepaid expenses and other current assets	65,000	58,000
Total current assets	7,394,000	6,362,000
Equipment and leasehold improvements, net of depreciation	1,807,000	662,000
Other non-current assets	70,000	70,000
Investment in South Korean joint venture	15,000	19,000
Right of use, operating leases, net of amortization	1,019,000	1,092,000
Total assets	10,305,000	8,205,000
Current liabilities:
Total	1,606,000	1,488,000
Debt obligation	66,000	66,000
Contract liabilities	19,000	303,000
Lease liabilities	105,000	105,000
Deposits	82,000	117,000
Total current liabilities	3,200,000	2,710,000
Long-term liabilities:
Debt obligations, net of current	180,000	289,000
Lease liabilities, net of current	944,000	1,004,000
Total long-term liabilities	1,124,000	1,293,000
Total liabilities	4,324,000	4,003,000
STOCKHOLDERS’ EQUITY:
Preferred Series A, $0.00067 Par Value, 50,000,000 Shares Authorized, no Shares Issued and Outstanding, at September 30, 2024 and December 31, 2023	0	0
Common stock, $0.00067 Par Value, 550,000,000 Shares Authorized, 301,163,538 and 292,945,747 Shares Issued, at September 30, 2024 and December 31, 2023	202,000	196,000
Additional paid-in capital	157,091,000	154,023,000
Accumulated deficit	(148,486,000)	(147,098,000)
Accumulated other comprehensive loss	(230,000)	(277,000)
Total BioLargo Inc. and subsidiaries stockholders’ equity	8,577,000	6,844,000
Non-controlling interest (Note 8, 9, 10)	(2,596,000)	(2,642,000)
Total stockholders’ equity	5,981,000	4,202,000
Total liabilities and stockholders’ equity	10,305,000	8,205,000
Entities, Excluding Partially Owned Subsidiary [Member]
Current liabilities:
Total	1,606,000	1,488,000
Partially Owned Subsidiary [Member]
Current liabilities:
Total	1,188,000	397,000
Clyra Medical Debt Obligations [Member]
Current liabilities:
Clyra Medical debt obligations	$ 134,000	$ 234,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Convertible Preferred Stock, Par Value (in dollars per share)	$ 0.00067	$ 0.00067
Convertible Preferred Stock, Shares Authorized (in shares)	50,000,000	50,000,000
Convertible Preferred Stock, Shares Issued (in shares)	0	0
Convertible Preferred Stock, Shares Outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.00067	$ 0.00067
Common stock, shares authorized (in shares)	550,000,000	550,000,000
Common stock, shares issued (in shares)	301,163,538	292,945,747

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenue
Revenue from Contract with Customer, Including Assessed Tax	$ 4,351,000	$ 2,672,000	$ 14,122,000	$ 7,860,000
Cost of revenue
Cost of Goods and Services Sold	(2,629,000)	(1,237,000)	(8,019,000)	(3,794,000)
Gross profit	1,722,000	1,435,000	6,103,000	4,066,000
Selling, general and administrative expenses	2,093,000	2,278,000	6,720,000	5,794,000
Research and development	690,000	694,000	2,098,000	1,846,000
Total operating expenses	2,783,000	2,972,000	8,818,000	7,640,000
Operating loss	(1,061,000)	(1,537,000)	(2,715,000)	(3,574,000)
Other income (expense):
Interest income (expense)	1,000	(12,000)	(12,000)	(72,000)
Tax credit (reversal)	0	41,000	0	(14,000)
PPP loan forgiveness	0	0	97,000	0
Grant income	0	0	15,000	32,000
Total other income (expense):	1,000	29,000	100,000	(54,000)
Net loss	(1,060,000)	(1,508,000)	(2,615,000)	(3,628,000)
Net loss attributable to noncontrolling interest	(523,000)	(308,000)	(1,227,000)	(853,000)
Net loss attributable to common stockholders	$ (537,000)	$ (1,200,000)	$ (1,388,000)	$ (2,775,000)
Net loss per share attributable to common stockholders:
Loss per share attributable to stockholders – basic and diluted (in dollars per share)	$ (0.002)	$ (0.004)	$ (0.005)	$ (0.01)
Weighted average number of common shares outstanding: (in shares)	300,488,824	287,943,346	297,090,396	284,559,487
Comprehensive loss:
Net loss	$ (1,060,000)	$ (1,508,000)	$ (2,615,000)	$ (3,628,000)
Foreign translation adjustment (unaudited)	12,000	1,000	47,000	(12,000)
Comprehensive loss	(1,048,000)	(1,507,000)	(2,568,000)	(3,640,000)
Comprehensive loss attributable to noncontrolling interest	(523,000)	(308,000)	(1,227,000)	(853,000)
Comprehensive loss attributable to common stockholders	(525,000)	(1,199,000)	(1,341,000)	(2,787,000)
Product [Member]
Revenue
Revenue from Contract with Customer, Including Assessed Tax	3,935,000	2,529,000	13,397,000	7,392,000
Cost of revenue
Cost of Goods and Services Sold	(2,342,000)	(1,170,000)	(7,510,000)	(3,533,000)
Service [Member]
Revenue
Revenue from Contract with Customer, Including Assessed Tax	416,000	143,000	725,000	468,000
Cost of revenue
Cost of Goods and Services Sold	$ (287,000)	$ (67,000)	$ (509,000)	$ (261,000)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Clyra Medical Technologies [Member] Common Stock [Member]	Clyra Medical Technologies [Member] Additional Paid-in Capital [Member]	Clyra Medical Technologies [Member] Retained Earnings [Member]	Clyra Medical Technologies [Member] AOCI Attributable to Parent [Member]	Clyra Medical Technologies [Member] Noncontrolling Interest [Member]	Clyra Medical Technologies [Member]	BioLargo Energy Technologies, Inc (BETI) [Member] Common Stock [Member]	BioLargo Energy Technologies, Inc (BETI) [Member] Additional Paid-in Capital [Member]	BioLargo Energy Technologies, Inc (BETI) [Member] Retained Earnings [Member]	BioLargo Energy Technologies, Inc (BETI) [Member] AOCI Attributable to Parent [Member]	BioLargo Energy Technologies, Inc (BETI) [Member] Noncontrolling Interest [Member]	BioLargo Energy Technologies, Inc (BETI) [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Noncontrolling Interest [Member]	Total
Balance (in shares) at Dec. 31, 2022													278,462,706
Balance at Dec. 31, 2022													$ 186,000	$ 148,435,000	$ (143,594,000)	$ (149,000)	$ (2,867,000)	$ 2,011,000
Sale of stock for cash, net of offering costs of $39 (unaudited) (in shares)													4,201,402
Sale of stock for cash, net of offering costs of $39 (unaudited)													$ 3,000	797,000	0	0	0	800,000
Issuance of stock for services (unaudited) (in shares)													930,490
Issuance of stock for services (unaudited)													$ 1,000	206,000	0	0	0	207,000
Stock option compensation expense (unaudited)													0	195,000	0	0	0	195,000
Stock option compensation expense Clyra (unaudited)	$ 0	$ 61,000	$ 0	$ 0	$ 0	$ 61,000
Stock for service Clyra (unaudited)	0	0	0	0	225,000	225,000	$ 0	$ 0	$ 0	$ 0	$ 550,000	$ 550,000
Clyra dividend Series A Preferred stock (unaudited)	0	0	0	0	(27,000)	(27,000)
Noncontrolling interest allocation (unaudited)													0	467,000	0	0	(467,000)	0
Net loss													0	0	(247,000)	0	(247,000)	(494,000)
Foreign currency translation (unaudited)													$ 0	0	0	(6,000)	0	(6,000)
Issuance of common stock in exchange for BETI shares (unaudited) (in shares)													527,983
Foreign translation adjustment (unaudited)													$ 0	0	0	(6,000)	0	(6,000)
Balance (in shares) at Mar. 31, 2023													284,122,581
Balance at Mar. 31, 2023													$ 190,000	150,191,000	(143,841,000)	(155,000)	(2,833,000)	3,552,000
Common stock offering costs of $15 (unaudited)													(3,000)	(797,000)	0	0	0	(800,000)
Warrant issued for interest (unaudited)													$ 0	30,000	0	0	0	30,000
Balance (in shares) at Dec. 31, 2022													278,462,706
Balance at Dec. 31, 2022													$ 186,000	148,435,000	(143,594,000)	(149,000)	(2,867,000)	2,011,000
Net loss																		(3,628,000)
Foreign currency translation (unaudited)																		(12,000)
Foreign translation adjustment (unaudited)																		(12,000)
Balance (in shares) at Sep. 30, 2023													288,626,570
Balance at Sep. 30, 2023													$ 193,000	153,406,000	(146,369,000)	(161,000)	(3,252,000)	3,817,000
Balance (in shares) at Mar. 31, 2023													284,122,581
Balance at Mar. 31, 2023													$ 190,000	150,191,000	(143,841,000)	(155,000)	(2,833,000)	3,552,000
Sale of stock for cash, net of offering costs of $39 (unaudited) (in shares)													2,677,169
Sale of stock for cash, net of offering costs of $39 (unaudited)													$ 2,000	492,000	0	0	0	494,000
Issuance of stock for services (unaudited) (in shares)													420,911
Issuance of stock for services (unaudited)													$ 0	75,000	0	0	0	75,000
Stock option compensation expense (unaudited)													0	222,000	0	0	0	222,000
Stock option compensation expense Clyra (unaudited)	0	66,000	0	0	0	66,000
Stock for service Clyra (unaudited)	0	0	0	0	1,062,000	1,062,000
Clyra unit offering (unaudited)							0	0	0	0	330,000	330,000
Clyra dividend Series A Preferred stock (unaudited)	0	0	0	0	(45,000)	(45,000)
Noncontrolling interest allocation (unaudited)													0	1,461,000	0	0	(1,461,000)	0
Net loss													0	0	(1,328,000)	0	(298,000)	(1,626,000)
Foreign currency translation (unaudited)													0	0	0	(7,000)	0	(7,000)
Foreign translation adjustment (unaudited)													$ 0	0	0	(7,000)	0	(7,000)
Balance (in shares) at Jun. 30, 2023													287,220,661
Balance at Jun. 30, 2023													$ 192,000	152,507,000	(145,169,000)	(162,000)	(3,245,000)	4,123,000
Common stock offering costs of $15 (unaudited)													$ (2,000)	(492,000)	0	0	0	(494,000)
Sale of stock for cash, net of offering costs of $39 (unaudited) (in shares)													1,190,223
Sale of stock for cash, net of offering costs of $39 (unaudited)													$ 1,000	202,000	0	0	0	203,000
Issuance of stock for services (unaudited) (in shares)													215,686
Issuance of stock for services (unaudited)													$ 0	37,000	0	0	0	37,000
Stock option compensation expense (unaudited)													0	680,000	0	0	0	680,000
Stock option compensation expense Clyra (unaudited)	0	45,000	0	0	0	45,000
Stock for service Clyra (unaudited)	0	0	0	0	288,000	288,000
Clyra unit offering (unaudited)							$ 0	0	0	0	25,000	25,000
Clyra dividend Series A Preferred stock (unaudited)	0	0	0	0	(80,000)	(80,000)
Noncontrolling interest allocation (unaudited)													0	(68,000)	0	0	68,000	0
Net loss													0	0	(1,200,000)	0	(308,000)	(1,508,000)
Foreign currency translation (unaudited)													0	0	0	1,000	0	1,000
Stock option exercise (unaudited)	0	3,000	0	0	0	3,000
Foreign translation adjustment (unaudited)													$ 0	0	0	1,000	0	1,000
Balance (in shares) at Sep. 30, 2023													288,626,570
Balance at Sep. 30, 2023													$ 193,000	153,406,000	(146,369,000)	(161,000)	(3,252,000)	3,817,000
Common stock offering costs of $15 (unaudited)													$ (1,000)	(202,000)	0	0	0	(203,000)
Balance (in shares) at Dec. 31, 2023													292,945,747
Balance at Dec. 31, 2023													$ 196,000	154,023,000	(147,098,000)	(277,000)	(2,642,000)	4,202,000
Sale of stock for cash, net of offering costs of $39 (unaudited) (in shares)													2,160,348
Sale of stock for cash, net of offering costs of $39 (unaudited)													$ 1,000	487,000	0	0	0	488,000
Issuance of stock for services (unaudited) (in shares)													288,997
Issuance of stock for services (unaudited)													$ 1,000	82,000	0	0	0	83,000
Warrant exercise (unaudited)													0	75,000	0	0	0	75,000
Stock option compensation expense (unaudited)													0	429,000	0	0	0	429,000
Stock option compensation expense Clyra (unaudited)	0	59,000	0	0	0	59,000
Stock for service Clyra (unaudited)	0	52,000	0	0	0	52,000
Clyra unit offering (unaudited)	0	0	0	0	475,000	475,000							0	0	0	0	50,000	50,000
Clyra dividend Series A Preferred stock (unaudited)	0	0	0	0	(86,000)	(86,000)
Noncontrolling interest allocation (unaudited)													0	399,000	0	0	(399,000)	0
Net loss													0	0	(410,000)	0	(365,000)	(775,000)
Foreign currency translation (unaudited)													0	0	0	96,000	0	96,000
Foreign translation adjustment (unaudited)													$ 0	0	0	96,000	0	96,000
Balance (in shares) at Mar. 31, 2024													295,801,370
Balance at Mar. 31, 2024													$ 198,000	155,606,000	(147,508,000)	(181,000)	(2,967,000)	5,148,000
Common stock offering costs of $15 (unaudited)													$ (1,000)	(487,000)	0	0	0	(488,000)
Balance (in shares) at Dec. 31, 2023													292,945,747
Balance at Dec. 31, 2023													$ 196,000	154,023,000	(147,098,000)	(277,000)	(2,642,000)	4,202,000
Net loss																		(2,615,000)
Foreign currency translation (unaudited)																		47,000
Foreign translation adjustment (unaudited)																		47,000
Balance (in shares) at Sep. 30, 2024													301,163,538
Balance at Sep. 30, 2024													$ 202,000	157,091,000	(148,486,000)	(230,000)	(2,596,000)	5,981,000
Warrant exercise (unaudited) (in shares)													406,278
Balance (in shares) at Mar. 31, 2024													295,801,370
Balance at Mar. 31, 2024													$ 198,000	155,606,000	(147,508,000)	(181,000)	(2,967,000)	5,148,000
Sale of stock for cash, net of offering costs of $39 (unaudited) (in shares)													454,547
Sale of stock for cash, net of offering costs of $39 (unaudited)													$ 1,000	135,000	0	0	0	136,000
Issuance of stock for services (unaudited) (in shares)													446,989
Issuance of stock for services (unaudited)													$ 0	116,000	0	0	0	116,000
Warrant exercise (unaudited)													1,000	140,000	0	0	0	141,000
Stock option compensation expense (unaudited)													0	476,000	0	0	0	476,000
Stock option compensation expense Clyra (unaudited)	0	0	0	0	63,000	63,000
Stock for service Clyra (unaudited)	0	0	0	0	14,000	14,000
Clyra unit offering (unaudited)	0	0	0	0	640,000	640,000
Clyra dividend Series A Preferred stock (unaudited)	0	0	0	0	(86,000)	(86,000)
Noncontrolling interest allocation (unaudited)													0	(2,565,000)	0	0	2,565,000	0
Net loss													0	0	(441,000)	0	(339,000)	(780,000)
Foreign currency translation (unaudited)													$ 0	0	0	(61,000)	0	(61,000)
Issuance of common stock in exchange for BETI shares (unaudited) (in shares)							378,788
Issuance of common stock in exchange for BETI shares (unaudited)							$ 0	$ 0	$ 0	$ 0	$ 0	$ 0
Stock option exercise (unaudited) (in shares)													497,024
Stock option exercise (unaudited)													$ 0	85,000	0	0	0	85,000
Foreign translation adjustment (unaudited)													$ 0	0	0	(61,000)	0	(61,000)
Balance (in shares) at Jun. 30, 2024													298,140,188
Balance at Jun. 30, 2024													$ 200,000	153,993,000	(147,949,000)	(242,000)	(110,000)	5,892,000
Common stock offering costs of $15 (unaudited)													$ (1,000)	(135,000)	0	0	0	(136,000)
Balance (in shares) at Mar. 31, 2024													295,801,370
Balance at Mar. 31, 2024													$ 198,000	155,606,000	(147,508,000)	(181,000)	(2,967,000)	5,148,000
Balance (in shares) at Sep. 30, 2024													301,163,538
Balance at Sep. 30, 2024													$ 202,000	157,091,000	(148,486,000)	(230,000)	(2,596,000)	5,981,000
Warrant exercise (unaudited) (in shares)													561,470
Balance (in shares) at Jun. 30, 2024													298,140,188
Balance at Jun. 30, 2024													$ 200,000	153,993,000	(147,949,000)	(242,000)	(110,000)	5,892,000
Sale of stock for cash, net of offering costs of $39 (unaudited) (in shares)													0
Sale of stock for cash, net of offering costs of $39 (unaudited)													$ 0	15,000	0	0	0	15,000
Issuance of stock for services (unaudited) (in shares)													260,903
Issuance of stock for services (unaudited)													$ 0	63,000	0	0	0	63,000
Warrant exercise (unaudited)													2,000	538,000	0	0	0	540,000
Stock option compensation expense (unaudited)													0	194,000	0	0	0	194,000
Stock option compensation expense Clyra (unaudited)	0	0	0	0	43,000	43,000
Stock for service Clyra (unaudited)	0	0	0	0	37,000	37,000
Clyra unit offering (unaudited)	0	0	0	0	175,000	175,000
Clyra dividend Series A Preferred stock (unaudited)	0	0	0	0	(87,000)	(87,000)
Noncontrolling interest allocation (unaudited)													0	2,250,000	0	0	(2,250,000)	0
Net loss													0	0	(537,000)	0	(523,000)	(1,060,000)
Foreign currency translation (unaudited)													$ 0	0	0	12,000	0	12,000
Stock option exercise (unaudited) (in shares)													451,858
Stock option exercise (unaudited)													$ 0	68,000	0	0	0	68,000
Foreign translation adjustment (unaudited)													$ 0	0	0	12,000	0	12,000
Balance (in shares) at Sep. 30, 2024													301,163,538
Balance at Sep. 30, 2024													$ 202,000	157,091,000	(148,486,000)	(230,000)	(2,596,000)	5,981,000
Common stock offering costs of $15 (unaudited)													$ 0	$ (15,000)	$ 0	$ 0	$ 0	$ (15,000)
Clyra conversion of note payable and interest (unaudited)	$ 0	$ 0	$ 0	$ 0	$ 119,000	$ 119,000
Warrant exercise (unaudited) (in shares)													2,310,589

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024
Offering Cost	$ 15	$ 16	$ 39

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities
Net loss	$ (2,615,000)	$ (3,628,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock option compensation expense	1,264,000	1,269,000
Common stock issued for services	365,000	319,000
Bad debt expense	13,000	101,000
Excess and obsolete inventory	0	54,000
PPP loan forgiveness	(97,000)	0
Amortization of right-of-use operating lease assets	73,000	90,000
Lease liabilities, net	(60,000)	(78,000)
Interest expense related to amortization of the discount on note payable	0	3,000
Fair value of warrant issued for interest	0	30,000
Loss on investment in South Korean joint venture	4,000	18,000
Depreciation expense	115,000	94,000
Changes in assets and liabilities:
Accounts receivable	(610,000)	(490,000)
Inventories	(85,000)	(58,000)
Prepaid expenses and other assets	(7,000)	101,000
Deposits	(35,000)	(62,000)
Contract liabilities	(284,000)	(15,000)
Net cash used in operating activities	(1,290,000)	(2,363,000)
Cash flows from investing activities
Equipment purchases	(1,260,000)	(332,000)
Net cash used in investing activities	(1,260,000)	(332,000)
Cash flows from financing activities
Proceeds from sale of common stock	609,000	1,497,000
Proceeds from warrant exercise	756,000	0
Proceeds from option exercise	153,000	0
Repayment of debt obligations	(12,000)	(55,000)
Repayment by Clyra debt obligations	0	(27,000)
Net cash provided by financing activities	2,846,000	3,898,000
Net effect of foreign currency translation	47,000	(12,000)
Net change in cash	343,000	1,191,000
Cash and cash equivalents at beginning of period	3,539,000	1,851,000
Cash and cash equivalents at end of period	3,882,000	3,042,000
Supplemental disclosures of cash flow information
Interest	12,000	39,000
Income taxes	0	0
Short-term lease payments not included in lease liabilities	37,000	43,000
Non-cash investing and financing activities
Conversion of Clyra note payable into Clyra shares	84,000	1,860,000
Equipment added using capital lease	0	80,000
Clyra dividend Series A Preferred stock	259,000	152,000
Conversion of BETI Common Stock to BioLargo Common Stock [Member]
Non-cash investing and financing activities
Conversion of Common Stock	50,000	0
BETI Common Stock [Member]
Cash flows from financing activities
Proceeds from sale of common stock	50,000	905,000
Clyra Medical, Preferred Stock [Member]
Cash flows from financing activities
Proceeds from option exercise	0	3,000
Proceeds from sales of Clyra Series A Preferred stock	0	1,575,000
Clyra Medical Common Stock [Member]
Cash flows from financing activities
Proceeds from sale of common stock	1,290,000	0
Clyra Medical Technology Inc [Member]
Non-cash investing and financing activities
Conversion of Clyra note payable into Clyra shares	119,000	0
Entities, Excluding Partially Owned Subsidiary [Member]
Changes in assets and liabilities:
Accounts payable and accrued expenses	118,000	(52,000)
Partially Owned Subsidiary [Member]
Changes in assets and liabilities:
Accounts payable and accrued expenses	$ 551,000	$ (59,000)

Note 1 - Business and Organizat

Note 1 - Business and Organization	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1. Description of Business BioLargo, Inc. (“BioLargo”, or the “Company”) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination (per- and polyfluoroalkyl substances), advanced water and wastewater treatment, industrial odor control, air quality control, infection control, and myriad environmental remediation challenges. Our business strategy is straightforward: we invent or acquire technologies that we believe have the potential to be disruptive in large commercial markets; we develop and validate these technologies to advance and promote their commercial success as we leverage our considerable scientific, engineering, and entrepreneurial talent; we then monetize these technical assets through a variety of business structures that may Organization We are a Delaware corporation formed in 1991, five 2006; 2009; 2022; 2014; 2016. three 2012 2023; 2017; 2019. Liquidity / Going Concern For the three nine September 30, 2024 nine September 30, 2024 September 30, 2024 During the nine September 30, 2024 nine September 30, 2024 For these reasons, we continue to sell securities to ensure available working capital, both directly and through our subsidiaries; during the nine months ended September 30, 2024 nine September 30, 2024

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 2. Principles of Consolidation The condensed consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries, and partially owned subsidiaries BETI, BLEST and Clyra Medical. All intercompany accounts and transactions have been eliminated. The accounting and financial reporting policies of the Company conform, in all material respects, to accounting principles generally accepted in the United States of America (“GAAP”) and to general practices within the industry. The condensed consolidated financial statements in the Quarterly Report on Form 10 not 10 not December 31, 2023 10 April 1, 2024. nine September 30, 2024 not Foreign Currency The Company has designated the functional currency of BioLargo Canada, Inc., our Canadian subsidiary, to be the Canadian dollar. Therefore, translation gains and losses resulting from differences in exchange rates are recorded in accumulated other comprehensive loss. Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three one $250,000 not As of September 30, 2024 December 31, 2023 September 30, 2024 December 31, 2023 BioLargo, Inc. and subsidiaries $ 3,721 $ 3,142 Clyra Medical Technologies, Inc. 161 397 Total $ 3,882 $ 3,539 Accounts Receivable Accounts receivable are customer obligations that are unconditional. Accounts receivable are presented net of an allowance for doubtful accounts for expected credit losses, which represents an estimate of amounts that may not no not September 30, 2024 December 31, 2023 Credit Concentration We have a limited number of customers that account for significant portions of our revenue. During the three nine September 30, 2024 2023 10% Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Customer A 76 % 74 % 78 % 76 % At September 30, 2024 December 31, 2023 one September 30, 2024 December 31, 2023 Customer A 79 % 68 % Inventory Inventories are stated at the lower of cost or net realizable value using the average cost method. The allowance for obsolete inventory as of September 30, 2024 December 31, 2023 September 30, 2024 December 31, 2023 Raw material $ 113 $ 79 Finished goods 125 74 Total $ 238 $ 153 Other Non-Current Assets Other non-current assets consisted of (i) security deposits related to our business offices, (ii) three October 22, 2021, September 30, 2024 December 31, 2023 Patents $ 34 $ 34 Security deposits 36 36 Total $ 70 $ 70 Equity Method of Accounting On March 20, 2020, We account for our investment in the joint venture under the equity method of accounting. We have determined that while we have significant influence over the joint venture through our technology license and our position on the Board of Directors, we do not three nine September 30, 2024 2023 Impairment Long-lived and definite lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not no nine September 30, 2024 2023 Loss Per Share We report basic and diluted loss per share (“LPS”) for common and common share equivalents. Basic LPS is computed by dividing reported losses by the weighted average shares outstanding. Diluted LPS is computed by adding to the weighted average shares the dilutive effect if stock options and warrants were exercised into common stock. For the three nine September 30, 2024 2023 September 30, 2024 Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and revenues and expenses during the period reported. Actual results could differ from those estimates. Estimates are used when accounting for stock-based transactions, debt transactions, derivative liabilities, allowance for doubtful accounts, asset depreciation and amortization, impairment expense, among others. The methods, estimates and judgments we use in applying these most critical accounting policies have a significant impact on the results of our condensed consolidated financial statements. Share-Based Compensation Expense We recognize compensation expense for stock option awards on a straight-line basis over the applicable service period of the award, which is the vesting period. Fair value is determined on the grant date. Share-based compensation expense is based on the grant date fair value estimated using the Black-Scholes Option Pricing Model. For stock and stock options issued to consultants and other non-employees for services, the Company measures and records an expense as of the earlier of the date at which either: a commitment for performance by the non-employee has been reached or the non-employee’s performance is complete. The equity instruments are measured at the current fair value, and for stock options, the instruments are measured at fair value using the Black Scholes option model. The following methodology and assumptions were used to calculate share-based compensation for the nine September 30, 2024 2023 2024 2023 Non Plan 2018 Plan 2024 Plan Non Plan 2018 Plan Risk free interest rate 3.81 4.34 % 4.16% 3.75 4.34 % 4.15 % 3.48 4.15 % Expected volatility 95 117 % 99 102 % 95 96 % 112 % 112 114 % Expected dividend yield — — — — — Forfeiture rate — — — — — Life in years 10 10 10 10 10 Expected price volatility is the measure by which our stock price is expected to fluctuate during the expected term of an option. The expected volatility is derived from the historical daily change in the market price of our common stock, as we believe that historical volatility is the best indicator of future volatility. The risk-free interest rate used in the Black-Scholes calculation is based on the prevailing U.S. Treasury yield as determined by the U.S. Federal Reserve. We have never paid any cash dividends on our common stock and do not Warrants Warrants issued with our convertible and non-convertible debt instruments are accounted for under the fair value and relative fair value method. The warrant is first not. not not Non-Cash Transactions We determine the value assigned to each intangible we acquire, and/or services or products received for non-cash consideration of our common stock based on the market price of our common stock issued as consideration, at the date of the agreement of each transaction or when the service is rendered or product is received. Revenue Recognition We account for revenue in accordance with ASC 606, Step 1: Step 2: Step 3: Step 4: Step 5: The Company’s products are sold through a contract with the customer and a written purchase order, in which the details of the contract are defined including the transaction price and method of shipment. The only performance obligation is to create and ship the product, and each product has separate pricing. Revenue is recognized at a point in time when the goods are shipped if the agreement is FOB manufacturer, and when goods are delivered if FOB destination. Revenue is recognized with a reduction for sales discounts, as appropriate and negotiated in the customer’s purchase order. Service contracts are performed through a written contract, which specifies the performance obligations and the rate at which the services will be billed, typically by time and materials. Each service is separately negotiated and priced. Revenue is recognized as services are performed and completed, or, for services related to product installations, at the completion of the installation. A few contracts have called for milestone or fixed cost payments, where we invoice an agreed-to amount per month for the life of the contract. In these instances, completed work, billed hourly, is recognized as revenue. If the billing amount is greater or lesser than the completed work, a receivable or payable is created. These accounts are adjusted upon additional billings as the work is completed. To date, there have been no The Company has outstanding contract liability obligations of $19,000 and $303,000 as of September 30, 2024 December 31, 2023 nine September 30, 2024 September 30, 2024 December 31, 2023 September 30, 2024 December 31, 2023 not nine September 30, 2024 As we generate revenues from royalties or license fees from our intellectual property, a licensee will pay a license fee in one third Government Grants We have been awarded multiple research grants from the private and public Canadian research programs. The income we receive directly from grants is recorded as other income. We have been awarded over 80 first 2015. third third six eighteen not The grants typically provide for (i) recurring monthly amounts, (ii) reimbursement of costs for research talent for which we invoice to request payment, and (iii) ancillary cost reimbursement for research talent travel related costs. All awarded grants have specific requirements on how the money is spent, typically to employ researchers. None may Not no Income Taxes The asset and liability approach is used to recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of asset and liabilities. Deferred tax assets and liabilities are determined based on the differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect on deferred tax asset and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. We account for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement, presentation, and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. Under GAAP, the tax effects of a position are recognized only if it is “more-likely-than- not” not not” no no September 30, 2024 December 31, 2023 The Company assessed its earnings history, trends and estimates of future earnings and determined that the deferred tax asset could not September 30, 2024 December 31, 2023 100% The Company recognizes interest and penalties on income taxes as a component of income tax expense, should such an expense be realized. Fair Value of Financial Instruments Management believes the carrying amounts of the Company’s financial instruments as of September 30, 2024 December 31, 2023 Leases At inception of a lease contract, we assess whether the contract is, or contains, a lease. Our assessment is based on: ( 1 2 3 not no not not 12 not September 30, 2024 December 31, 2023 September 30, 2024 December 31, 2023 Equipment and Leasehold Improvements Equipment and leasehold improvements and are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which range from 3 - 10 years or the remaining lease term. Newly built leaseholds, additions, renewals, and betterments that significantly extend the life of the asset are capitalized. Expenditures for repairs and maintenance are charged to expense as incurred. For assets sold or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the accounts, and any related gain or loss is reflected in income for the period. Noncontrolling Interest A noncontrolling interest is defined as the portion of the equity in an entity not not 810 10 20, three September 30, 2024 December 31, 2023 September 30, 2024 December 31, 2023 September 30, 2024 December 31, 2023

Note 3 - Sale of Stock for Cash

Note 3 - Sale of Stock for Cash	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Stock Purchase Agreement [Text Block]	Note 3. Lincoln Park Financing On December 13, 2022, three may three 12 no first 1 December 23, 2022. January 19, 2023. During the three September 30, 2024, not nine September 30, 2024, During the three nine September 30, 2023, Unit Offerings We did not three September 30, 2024 nine September 30, 2024 seven six five 6, We did not three September 30, 2023. nine September 30, 2023, six five 6,

Note 4 - Debt Obligations

Note 4 - Debt Obligations	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 4. The following table summarizes our debt obligations outstanding as of September 30, 2024 December 31, 2023 not 8, September 30, 2024 December 31, 2023 Current portion of debt: SBA Paycheck Protection Program loan $ 43 $ 43 Vehicle loan, current portion 13 13 SBA EIDL Loan, matures July 2053, current portion 10 10 Total current portion of debt $ 66 $ 66 Long-term debt: SBA Paycheck Protection Program loans, matures May 2025 $ — $ 97 Vehicle loan, matures March 2029 45 55 SBA EIDL Loan, matures July 2053 135 137 Total long-term debt, net of current $ 180 $ 289 Total $ 246 $ 355 For the three nine September 30, 2024 For the three nine September 30, 2023 Vehicle loan On February 7, 2023, March 7, 2029. September 30, 2024 SBA Program Loans On June 28, 2024, On February 7, 2022, September 30, 2024 In July 2020, July 2053. September 30, 2024

Note 5 - Share-based Compensati

Note 5 - Share-based Compensation	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Compensation and Employee Benefit Plans [Text Block]	Note 5. Issuance of Common Stock in exchange for Services Payment of Officer Salaries On September 30, 2024 no three June 30, 2024, March 31, 2024. On September 30, 2023, two June 30, 2023, March 31, 2023, Payment of Consultant and Vendor Fees On September 30, 2024, June 30, 2024, March 31, 2024, On September 30, 2023, June 30, 2023, March 31, 2023, All of these offerings and sales were made in reliance on the exemption from registration contained in Section 4 2 not Stock Option Expense During the three nine September 30, 2024 three nine September 30, 2023 2024 2018 three nine September 30, 2024 three nine September 30, 2023 8. 2024 On June 13, 2024, 2024 “2024 may June 13, 2034. 2024 January 1 September 30, 2024 Activity for our stock options under the 2024 nine September 30, 2024 Options outstanding Weighted average price per share Weighted average remaining life Aggregate intrinsic Value(1) Balance, December 31, 2023 — $ — Granted 3,482,270 $ 0.25 Balance, September 30, 2024 3,482,270 $ 0.25 9.9 $ — Unvested (1,261,982 ) $ 0.24 Vested, September 30, 2024 2,220,288 $ 0.25 9.9 $ — ( 1 September 30, 2024 The options granted to purchase 3,482,270 shares during the nine September 30, 2024 As of September 30, 2024 four Extension of Agreement with Chief Financial Officer On August 13, 2024, February 1, 2008 ( August 13, 2024 ( January 31, 2025 ( one As the sole compensation for the Extended Term, Mr. Dargan was issued an option (“Option”) to purchase 300,000 shares of the Company’s common stock (this issuance is included in the total identified in (iv) above). The Option vests over the period of the Extended Term in monthly installments of 25,000 shares, so long as the agreement is in full force and effect. The Option is exercisable at $0.24 per share, the closing price of BioLargo’s common stock on the August 13, 2024 ten 2024 no no not one 2018 On June 22, 2018, 2018 “2018 may June 22, 2028. 2018 January 1 st September 30, 2024 2018 2018 Activity for our stock options under the 2018 nine September 30, 2024 2023 Options outstanding Weighted average price per share Weighted average remaining life Aggregate intrinsic Value(1) Balance, December 31, 2023 41,108,448 $ 0.19 Granted 1,547,938 $ 0.30 Exercised (485,000 ) $ 0.15 Balance, September 30, 2024 42,171,386 $ 0.19 7.0 $ 1,991,000 Unvested (3,623,430 ) $ 0.22 Vested, September 30, 2024 38,547,956 $ 0.19 6.3 $ 1,866,000 Balance, December 31, 2022 28,484,549 $ 0.19 Granted 8,219,920 $ 0.18 Balance, September 30, 2023 36,704,469 $ 0.19 Unvested (4,648,922 ) $ 0.15 Vested Balance, September 30, 2023 32,055,547 $ 0.19 8.0 ( 1 September 30, 2024. The options granted to purchase 1,547,938 shares during the nine September 30, 2024 As of September 30, 2024 four The options granted to purchase 8,219,920 shares during the nine September 30, 2023 March 31, 2023 ( June 30, 2023 ( September 30, 2023 ( $266,000; four 2007 On September 7, 2007, April 29, 2011, 2007 “2007 may September 7, 2017. September 2017, Activity for our stock options under the 2007 nine September 30, 2024 2023 Options Outstanding Weighted average price per share Weighted average remaining life Aggregate intrinsic Value(1) Balance, December 31, 2023 1,564,085 $ 0.61 Expired (406,585 ) $ 0.61 Vested Balance, September 30, 2024 1,157,500 $ 0.61 1.3 $ — Balance, December 31, 2022 1,904,085 $ 0.56 Expired (340,000 ) $ 0.30 Vested Balance, September 30, 2023 1,564,085 $ 0.61 2.3 ( 1 September 30, 2024 Non-Plan Options Activity of our non-plan stock options issued for the nine September 30, 2024 2023 Non-plan Options outstanding Weighted average price per share Weighted average remaining life Aggregate intrinsic Value (1) Balance, December 31, 2023 17,375,044 $ 0.39 Granted 85,251 $ 0.23 Expired (865,199 ) $ 0.51 Exercised (463,882 ) $ 0.17 Balance, September 30, 2024 16,131,214 $ 0.39 2.6 $ 130,000 Unvested (437,500 ) $ 0.45 Vested, September 30, 2024 15,693,714 $ 0.39 2.3 $ 130,000 Balance, December 31, 2022 19,023,829 $ 0.39 Granted 60,040 $ 0.20 Expired (1,205,550 ) $ 0.30 Balance, September 30, 2023 17,878,319 $ 0.39 Unvested (507,500 ) $ 0.45 Vested Balance, September 30, 2023 17,370,819 $ 0.39 3.6 ( 1 September 30, 2024 During the nine September 30, 2024 September 30, 2024 three During the nine September 30, 2024, During the nine September 30, 2023,

Note 6 - Warrants

Note 6 - Warrants	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Warrants [Text Block]	Note 6. We have certain warrants outstanding to purchase our common stock, at various prices, as described in the following table: Warrants outstanding Weighted average price per share Weighted average remaining life Aggregate intrinsic value (1) Balance, December 31, 2023 51,590,300 $ 0.27 Granted 4,127,516 $ 0.27 Exercised (3,278,337 ) $ 0.24 Expired (20,534,700 ) $ 0.23 Vested Balance, September 30, 2024 31,904,779 $ 0.29 2.6 $ — Balance, December 31, 2022 49,023,398 $ 0.26 Granted 10,669,896 $ 0.26 Expired (11,313,584 ) $ 0.23 Vested Balance, September 30, 2023 48,379,710 $ 0.27 3.5 ( 1 September 30, 2024 During the nine September 30, 2024 Warrants issued in Unit Offerings During the nine September 30, 2024 3 six five 3 During the nine September 30, 2023, 3 six five Warrant issued in conjunction with amendment to note payable On March 6, 2023, five Warrant Fair Value We use the Black-Scholes option pricing model to determine the relative fair value of warrants issued in conjunction with debt instruments, common stock, and for services. With respect to debt instruments, relative fair value is amortized over the life of the warrant. The principal assumptions we used in applying the Black-Scholes model were as follows: 2024 2023 Risk free interest rate 3.69 – 5.38 % 3.88 – 4.27 % Expected volatility 64 – 95 % 40 – 95 % Expected dividend yield — — Forfeiture rate — — Expected life in years .5 – 5 .5 – 5 The risk-free interest rate is based on U.S. Treasury yields in effect at the time of grant. Expected volatilities are based on historical volatility of our common stock. The expected life in years is based on the contract term of the warrant.

Note 7 - Accounts Payable and A

Note 7 - Accounts Payable and Accrued Expenses	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	Note 7. As of September 30, 2024 Category BioLargo ONM BLEST Canada BETI BEST Intercompany amounts Totals Accounts payable $ 262 $ 1,123 $ 139 $ 39 $ 87 $ — $ (87 ) $ 1,563 Accrued payroll 6 — 37 — — — — 43 Total $ 1,606 As of December 31, 2023 Category BioLargo ONM BLEST Canada BETI BEST Intercompany amounts Totals Accounts payable $ 163 $ 964 $ 34 $ 93 40 $ — $ (82 ) $ 1,212 Accrued payroll 49 86 116 — — — — 251 Accrued interest 25 — — — — — — 25 Total $ 1,488 See Note 8, Amounts owed by ONM Environmental are comprised primarily of amounts owed to suppliers for goods and were not

Note 8 - Noncontrolling Interes

Note 8 - Noncontrolling Interest - Clyra Medical	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Noncontrolling Interest Disclosure [Text Block]	Note 8. Clyra Medical As discussed in Note 2 Debt Obligations of Clyra Medical Promissory Note On April 8, 2022, April 8, 2024, may July 2024, Line of Credit On June 30, 2020, may On December 13, 2022, September 30, 2024 January 9, 2023, As of September 30, 2024 Equity Transactions On December 15, 2023, one 1 During the three September 30, 2024 three June 30, 2024, three March 31, 2024, no As of September 30, 2024 December 31, 2023 September 30, 2024 December 31, 2023 BioLargo Conversion of Intercompany Balances In June 2024, Sales of Common Stock During the nine September 30, 2024 February 28, 2027, five During the nine September 30, 2023 not Sales of Series A Preferred Stock In an offering that closed in October 2023, 3 no one may September 30, 2024 December 31, 2023 $241,000, may 20% 30 may January 1, 2025, June 30, 2026. Clyra Stock Options Clyra Options Outstanding Weighted average price per share Weighted average remaining life Balance, December 31, 2023 1,478,922 $ 0.31 Granted 72,610 $ 4.18 Vested Balance, September 30, 2024 1,551,532 $ 1.20 6.4 Balance, December 31, 2022 1,583,329 $ 0.06 Granted 85,815 1.46 Exercised (296,389 ) 1.00 Vested Balance, September 30, 2023 1,372,755 $ 0.98 6.1 Clyra issues options to its employees and consultants in lieu of compensation owed on a regular basis. The fair value of the options issued totaled $131,000 in the nine September 30, 2024 nine September 30, 2023 nine September 30, 2024 2023 ant of $4.50 and $2. 71 no September 30, 2024 December 31, 2023 Risk free interest rate 3.95 - 4.34 % 3.48 - 4.45 % Expected volatility 43 - 49 % 40 - 49 % Expected dividend yield — — Forfeiture rate — — Expected life in years 10 10 Clyra Warrants Clyra Options Outstanding Weighted average price per share Weighted average remaining life Balance, December 31, 2023 749,911 $ 3.74 Granted 146,083 $ 7.50 Vested Balance, September 30, 2024 895,994 $ 4.03 2.2 Balance, December 31, 2022 207,513 $ 3.72 Granted 538,898 3.72 Vested Balance, September 30, 2023 746,411 $ 3.72 3.0 As part of the Clyra unit offering, it issued three nine September 30, 2024 2023 ant of $4.50 and $2. 71 no Accounts Payable and Accrued Expenses At September 30, 2024 December 31, 2023 Category 2024 2023 Accounts payable $ 664 $ 135 Accrued dividend 501 $ 242 Accrued payroll 23 7 Accrued interest — 13 Total $ 1,188 $ 397

Note 9 - BioLargo Engineering,

Note 9 - BioLargo Engineering, Science and Technologies, LLC	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Wholly-Owned Subsidiary [Text Block]	Note 9. In September 2017, three six two no five September 30, 2024 December 31, 2023,

Note 10 - BioLargo Energy Techn

Note 10 - BioLargo Energy Technologies, Inc.	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Noncontrolling Interest Disclosure [Text Block]	Note 8. Clyra Medical As discussed in Note 2 Debt Obligations of Clyra Medical Promissory Note On April 8, 2022, April 8, 2024, may July 2024, Line of Credit On June 30, 2020, may On December 13, 2022, September 30, 2024 January 9, 2023, As of September 30, 2024 Equity Transactions On December 15, 2023, one 1 During the three September 30, 2024 three June 30, 2024, three March 31, 2024, no As of September 30, 2024 December 31, 2023 September 30, 2024 December 31, 2023 BioLargo Conversion of Intercompany Balances In June 2024, Sales of Common Stock During the nine September 30, 2024 February 28, 2027, five During the nine September 30, 2023 not Sales of Series A Preferred Stock In an offering that closed in October 2023, 3 no one may September 30, 2024 December 31, 2023 $241,000, may 20% 30 may January 1, 2025, June 30, 2026. Clyra Stock Options Clyra Options Outstanding Weighted average price per share Weighted average remaining life Balance, December 31, 2023 1,478,922 $ 0.31 Granted 72,610 $ 4.18 Vested Balance, September 30, 2024 1,551,532 $ 1.20 6.4 Balance, December 31, 2022 1,583,329 $ 0.06 Granted 85,815 1.46 Exercised (296,389 ) 1.00 Vested Balance, September 30, 2023 1,372,755 $ 0.98 6.1 Clyra issues options to its employees and consultants in lieu of compensation owed on a regular basis. The fair value of the options issued totaled $131,000 in the nine September 30, 2024 nine September 30, 2023 nine September 30, 2024 2023 ant of $4.50 and $2. 71 no September 30, 2024 December 31, 2023 Risk free interest rate 3.95 - 4.34 % 3.48 - 4.45 % Expected volatility 43 - 49 % 40 - 49 % Expected dividend yield — — Forfeiture rate — — Expected life in years 10 10 Clyra Warrants Clyra Options Outstanding Weighted average price per share Weighted average remaining life Balance, December 31, 2023 749,911 $ 3.74 Granted 146,083 $ 7.50 Vested Balance, September 30, 2024 895,994 $ 4.03 2.2 Balance, December 31, 2022 207,513 $ 3.72 Granted 538,898 3.72 Vested Balance, September 30, 2023 746,411 $ 3.72 3.0 As part of the Clyra unit offering, it issued three nine September 30, 2024 2023 ant of $4.50 and $2. 71 no Accounts Payable and Accrued Expenses At September 30, 2024 December 31, 2023 Category 2024 2023 Accounts payable $ 664 $ 135 Accrued dividend 501 $ 242 Accrued payroll 23 7 Accrued interest — 13 Total $ 1,188 $ 397
BioLargo Energy Technologies, Inc (BETI) [Member]
Notes to Financial Statements
Noncontrolling Interest Disclosure [Text Block]	Note 10. BioLargo Energy Technologies, Inc. (“BETI”) was formed for the purpose of commercializing a proprietary liquid sodium battery technology. BioLargo purchased 9,000,000 shares of its common stock upon its formation and was initially its sole stockholder. During the nine September 30, 2024 one may 20 December 31, 2025. During the nine September 30, 2024 30 As of September 30, 2024 During the three September 30, 2023, one nine September 30, 2023, 16 may 20 June 30, 2025.

Note 11 - Business Segment Info

Note 11 - Business Segment Information	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	Note 11. BioLargo has six 1. ONM Environmental -- which sells odor and volatile organic control products and services, located in Westminster, California; 2. Clyra Medical Technologies (“Clyra Medical”) -- which develops and sells medical products based on our technologies, located in Tampa, Florida; 3. BioLargo Engineering (BLEST) -- which provides professional engineering services on a time and materials basis for outside clients and supports our internal operations as needed, located in Oak Ridge, Tennessee; 4. BioLargo Canada, Inc. (“Canada”) – the main hub of our scientists researching and developing our technologies, operating out of the University of Alberta, Edmonton, Canada; and 5. BioLargo Energy Technologies, Inc. (“BETI”) – which is developing our proprietary battery technology. 6. BioLargo Equipment Solutions & Technologies, Inc. (“BEST”) – which manages the sales and distribution of our water treatment products and related services. Other than ONM Environmental, none third The segment information for the three nine September 30, 2024 2023 Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Revenue ONM Environmental $ 3,853 $ 2,513 $ 12,437 $ 7,374 BLEST 824 843 2,439 1,742 BioLargo Canada — 22 — 31 Clyra Medical — 14 — 20 Intersegment revenue (326 ) (720 ) (754 ) (1,307 ) Total $ 4,351 $ 2,672 $ 14,122 $ 7,860 Stock option expense BioLargo corporate $ (194 ) $ (680 ) $ (1,099 ) $ (1,097 ) Clyra Medical (43 ) (45 ) (165 ) (172 ) Total $ (237 ) $ (725 ) $ (1,264 ) $ (1,269 ) Depreciation expense BioLargo corporate $ (9 ) $ (10 ) $ (28 ) $ (25 ) ONM Environmental (10 ) (5 ) (27 ) (15 ) BLEST (17 ) (28 ) (53 ) (47 ) Clyra Medical (3 ) (3 ) (7 ) (7 ) Total $ (39 ) $ (46 ) $ (115 ) $ (94 ) Research and development expense BioLargo corporate $ (301 ) $ (234 ) $ (838 ) $ (665 ) ONM Environmental — (14 ) — (14 ) BLEST (157 ) (433 ) (845 ) (971 ) BETI (133 ) (537 ) (346 ) (840 ) BioLargo Canada (134 ) (128 ) (311 ) (401 ) Clyra Medical (291 ) (68 ) (512 ) (262 ) Intersegment R&D 326 720 754 1,307 Total $ (690 ) $ (694 ) $ (2,098 ) $ (1,846 ) Operating income (loss) BioLargo corporate $ (798 ) $ (797 ) $ (3,165 ) $ (2,230 ) ONM Environmental 1,382 969 4,668 2,786 BLEST (375 ) (568 ) (1,067 ) (1,388 ) BETI (194 ) (559 ) (575 ) (943 ) BEST (59 ) — (174 ) — BioLargo Canada (160 ) (155 ) (383 ) (549 ) Clyra Medical (857 ) (427 ) (2,019 ) (1,250 ) Total $ (1,061 ) $ (1,537 ) $ (2,715 ) $ (3,574 ) Interest income (expense) BioLargo corporate $ (3 ) $ (3 ) $ (6 ) $ (43 ) ONM Environmental 13 (1 ) 16 (5 ) Clyra Medical (9 ) (8 ) (22 ) (25 ) BioLargo Canada — — — 1 Total $ 1 $ (12 ) $ (12 ) $ (72 ) As of September 30, 2024 BioLargo ONM BLEST CLYRA BETI BEST Canada Elimination Total Tangible assets $ 562 $ 6,376 $ 891 $ 1,440 $ 7 $ — $ 58 $ (63 ) $ 9,271 Right of use operating lease 349 — 670 — — — — — 1,019 Investment in South Korean joint venture 15 — — — — — — — 15 Total $ 926 $ 6,376 $ 1,561 $ 1,440 $ 7 $ — $ 58 $ (63 ) $ 10,305 As of December 31, 2023 BioLargo ONM BLEST CLYRA BETI BEST Canada Elimination Total Tangible assets $ 942 $ 4,624 $ 1,083 $ 432 $ 4 $ — $ 50 $ (41 ) $ 7,094 Right of use operating lease 394 — 698 — — — — — 1,092 Investment in South Korean joint venture 19 — — — — — — — 19 Total $ 1,355 $ 4,624 $ 1,781 $ 432 $ 4 $ — $ 50 $ (41 ) $ 8,205

Note 12 - Leases

Note 12 - Leases	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Lessor, Operating Leases [Text Block]	Note 12. Office Leases W e have long-term operating leases for office, industrial and laboratory space in Westminster, California, Oak Ridge, Tennessee, and Alberta, Canada. Payments made under operating leases are charged to the Consolidated Statement of Operations and Comprehensive Loss on a straight-line basis over the term of the operating lease agreement. Short-term leases less than one not three nine September 30, 2024 , rental expense totaled $92,000 and $268,000; for the three nine September 30, 2023 , rental expense totaled $88,000 and $254,000. The lease of our Westminster facility expires August 2024. one None not no September 30, 2024 seven Future minimum lease payments under noncancelable leases, reconciled to the Company’s discounted operating lease liabilities are as follows: BioLargo Year ending Corp / ONM BLEST Total December 31, 2024 31,000 39,000 70,000 December 31, 2025 125,000 157,000 282,000 December 31, 2026 129,000 160,000 289,000 December 31, 2027 133,000 163,000 296,000 December 31, 2028 79,000 166,000 245,000 Thereafter — 654,000 654,000 Total minimum lease payments $ 497,000 $ 1,339,000 $ 1,836,000 Less imputed interest (787,000 ) Total operating lease liabilities $ 1,049,000

Note 13 - Subsequent Events

Note 13 - Subsequent Events	9 Months Ended
	Sep. 30, 2024
Notes to Financial Statements
Subsequent Events [Text Block]	Note 13. Stock Issuances From October 1, 2024, November 12, 2024, Clyra Equipment Refinance From October 1, 2024, November 12, 2024, two Clyra Sale of Common Stock From October 1, 2024, November 12, 2024,

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2024
Insider Trading Arr Line Items
Material Terms of Trading Arrangement [Text Block]		5. Other Information None
Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The condensed consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries, and partially owned subsidiaries BETI, BLEST and Clyra Medical. All intercompany accounts and transactions have been eliminated. The accounting and financial reporting policies of the Company conform, in all material respects, to accounting principles generally accepted in the United States of America (“GAAP”) and to general practices within the industry. The condensed consolidated financial statements in the Quarterly Report on Form 10 not 10 not December 31, 2023 10 April 1, 2024. nine September 30, 2024 not
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency The Company has designated the functional currency of BioLargo Canada, Inc., our Canadian subsidiary, to be the Canadian dollar. Therefore, translation gains and losses resulting from differences in exchange rates are recorded in accumulated other comprehensive loss.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three one $250,000 not As of September 30, 2024 December 31, 2023 September 30, 2024 December 31, 2023 BioLargo, Inc. and subsidiaries $ 3,721 $ 3,142 Clyra Medical Technologies, Inc. 161 397 Total $ 3,882 $ 3,539
Accounts Receivable [Policy Text Block]	Accounts Receivable Accounts receivable are customer obligations that are unconditional. Accounts receivable are presented net of an allowance for doubtful accounts for expected credit losses, which represents an estimate of amounts that may not no not September 30, 2024 December 31, 2023
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Credit Concentration We have a limited number of customers that account for significant portions of our revenue. During the three nine September 30, 2024 2023 10% Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Customer A 76 % 74 % 78 % 76 % At September 30, 2024 December 31, 2023 one September 30, 2024 December 31, 2023 Customer A 79 % 68 %
Inventory, Policy [Policy Text Block]	Inventory Inventories are stated at the lower of cost or net realizable value using the average cost method. The allowance for obsolete inventory as of September 30, 2024 December 31, 2023 September 30, 2024 December 31, 2023 Raw material $ 113 $ 79 Finished goods 125 74 Total $ 238 $ 153
Other Assets, Policy [Policy Text Block]	Other Non-Current Assets Other non-current assets consisted of (i) security deposits related to our business offices, (ii) three October 22, 2021, September 30, 2024 December 31, 2023 Patents $ 34 $ 34 Security deposits 36 36 Total $ 70 $ 70
Equity Method Investments [Policy Text Block]	Equity Method of Accounting On March 20, 2020, We account for our investment in the joint venture under the equity method of accounting. We have determined that while we have significant influence over the joint venture through our technology license and our position on the Board of Directors, we do not three nine September 30, 2024 2023
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment Long-lived and definite lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not no nine September 30, 2024 2023
Earnings Per Share, Policy [Policy Text Block]	Loss Per Share We report basic and diluted loss per share (“LPS”) for common and common share equivalents. Basic LPS is computed by dividing reported losses by the weighted average shares outstanding. Diluted LPS is computed by adding to the weighted average shares the dilutive effect if stock options and warrants were exercised into common stock. For the three nine September 30, 2024 2023 September 30, 2024
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and revenues and expenses during the period reported. Actual results could differ from those estimates. Estimates are used when accounting for stock-based transactions, debt transactions, derivative liabilities, allowance for doubtful accounts, asset depreciation and amortization, impairment expense, among others. The methods, estimates and judgments we use in applying these most critical accounting policies have a significant impact on the results of our condensed consolidated financial statements.
Share-Based Payment Arrangement [Policy Text Block]	Share-Based Compensation Expense We recognize compensation expense for stock option awards on a straight-line basis over the applicable service period of the award, which is the vesting period. Fair value is determined on the grant date. Share-based compensation expense is based on the grant date fair value estimated using the Black-Scholes Option Pricing Model. For stock and stock options issued to consultants and other non-employees for services, the Company measures and records an expense as of the earlier of the date at which either: a commitment for performance by the non-employee has been reached or the non-employee’s performance is complete. The equity instruments are measured at the current fair value, and for stock options, the instruments are measured at fair value using the Black Scholes option model. The following methodology and assumptions were used to calculate share-based compensation for the nine September 30, 2024 2023 2024 2023 Non Plan 2018 Plan 2024 Plan Non Plan 2018 Plan Risk free interest rate 3.81 4.34 % 4.16% 3.75 4.34 % 4.15 % 3.48 4.15 % Expected volatility 95 117 % 99 102 % 95 96 % 112 % 112 114 % Expected dividend yield — — — — — Forfeiture rate — — — — — Life in years 10 10 10 10 10 Expected price volatility is the measure by which our stock price is expected to fluctuate during the expected term of an option. The expected volatility is derived from the historical daily change in the market price of our common stock, as we believe that historical volatility is the best indicator of future volatility. The risk-free interest rate used in the Black-Scholes calculation is based on the prevailing U.S. Treasury yield as determined by the U.S. Federal Reserve. We have never paid any cash dividends on our common stock and do not
Warrant Policy [Policy Text Block]	Warrants Warrants issued with our convertible and non-convertible debt instruments are accounted for under the fair value and relative fair value method. The warrant is first not. not not
Non Cash Transactions [Policy Text Block]	Non-Cash Transactions We determine the value assigned to each intangible we acquire, and/or services or products received for non-cash consideration of our common stock based on the market price of our common stock issued as consideration, at the date of the agreement of each transaction or when the service is rendered or product is received.
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition We account for revenue in accordance with ASC 606, Step 1: Step 2: Step 3: Step 4: Step 5: The Company’s products are sold through a contract with the customer and a written purchase order, in which the details of the contract are defined including the transaction price and method of shipment. The only performance obligation is to create and ship the product, and each product has separate pricing. Revenue is recognized at a point in time when the goods are shipped if the agreement is FOB manufacturer, and when goods are delivered if FOB destination. Revenue is recognized with a reduction for sales discounts, as appropriate and negotiated in the customer’s purchase order. Service contracts are performed through a written contract, which specifies the performance obligations and the rate at which the services will be billed, typically by time and materials. Each service is separately negotiated and priced. Revenue is recognized as services are performed and completed, or, for services related to product installations, at the completion of the installation. A few contracts have called for milestone or fixed cost payments, where we invoice an agreed-to amount per month for the life of the contract. In these instances, completed work, billed hourly, is recognized as revenue. If the billing amount is greater or lesser than the completed work, a receivable or payable is created. These accounts are adjusted upon additional billings as the work is completed. To date, there have been no The Company has outstanding contract liability obligations of $19,000 and $303,000 as of September 30, 2024 December 31, 2023 nine September 30, 2024 September 30, 2024 December 31, 2023 September 30, 2024 December 31, 2023 not nine September 30, 2024 As we generate revenues from royalties or license fees from our intellectual property, a licensee will pay a license fee in one third
Government Grants [Policy Text Block]	Government Grants We have been awarded multiple research grants from the private and public Canadian research programs. The income we receive directly from grants is recorded as other income. We have been awarded over 80 first 2015. third third six eighteen not The grants typically provide for (i) recurring monthly amounts, (ii) reimbursement of costs for research talent for which we invoice to request payment, and (iii) ancillary cost reimbursement for research talent travel related costs. All awarded grants have specific requirements on how the money is spent, typically to employ researchers. None may Not no
Income Tax, Policy [Policy Text Block]	Income Taxes The asset and liability approach is used to recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of asset and liabilities. Deferred tax assets and liabilities are determined based on the differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect on deferred tax asset and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. We account for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement, presentation, and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. Under GAAP, the tax effects of a position are recognized only if it is “more-likely-than- not” not not” no no September 30, 2024 December 31, 2023 The Company assessed its earnings history, trends and estimates of future earnings and determined that the deferred tax asset could not September 30, 2024 December 31, 2023 100% The Company recognizes interest and penalties on income taxes as a component of income tax expense, should such an expense be realized.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments Management believes the carrying amounts of the Company’s financial instruments as of September 30, 2024 December 31, 2023
Lessee, Leases [Policy Text Block]	Leases At inception of a lease contract, we assess whether the contract is, or contains, a lease. Our assessment is based on: ( 1 2 3 not no not not 12 not September 30, 2024 December 31, 2023 September 30, 2024 December 31, 2023
Property, Plant and Equipment, Policy [Policy Text Block]	Equipment and Leasehold Improvements Equipment and leasehold improvements and are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which range from 3 - 10 years or the remaining lease term. Newly built leaseholds, additions, renewals, and betterments that significantly extend the life of the asset are capitalized. Expenditures for repairs and maintenance are charged to expense as incurred. For assets sold or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the accounts, and any related gain or loss is reflected in income for the period.
Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]	Noncontrolling Interest A noncontrolling interest is defined as the portion of the equity in an entity not not 810 10 20, three September 30, 2024 December 31, 2023 September 30, 2024 December 31, 2023 September 30, 2024 December 31, 2023

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Schedule of Cash and Cash Equivalents [Table Text Block]	September 30, 2024 December 31, 2023 BioLargo, Inc. and subsidiaries $ 3,721 $ 3,142 Clyra Medical Technologies, Inc. 161 397 Total $ 3,882 $ 3,539
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Customer A 76 % 74 % 78 % 76 % September 30, 2024 December 31, 2023 Customer A 79 % 68 %
Schedule of Inventory, Current [Table Text Block]	September 30, 2024 December 31, 2023 Raw material $ 113 $ 79 Finished goods 125 74 Total $ 238 $ 153
Schedule of Other Assets, Noncurrent [Table Text Block]	September 30, 2024 December 31, 2023 Patents $ 34 $ 34 Security deposits 36 36 Total $ 70 $ 70
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2024 2023 Non Plan 2018 Plan 2024 Plan Non Plan 2018 Plan Risk free interest rate 3.81 4.34 % 4.16% 3.75 4.34 % 4.15 % 3.48 4.15 % Expected volatility 95 117 % 99 102 % 95 96 % 112 % 112 114 % Expected dividend yield — — — — — Forfeiture rate — — — — — Life in years 10 10 10 10 10

Note 4 - Debt Obligations (Tabl

Note 4 - Debt Obligations (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Schedule of Debt [Table Text Block]	September 30, 2024 December 31, 2023 Current portion of debt: SBA Paycheck Protection Program loan $ 43 $ 43 Vehicle loan, current portion 13 13 SBA EIDL Loan, matures July 2053, current portion 10 10 Total current portion of debt $ 66 $ 66 Long-term debt: SBA Paycheck Protection Program loans, matures May 2025 $ — $ 97 Vehicle loan, matures March 2029 45 55 SBA EIDL Loan, matures July 2053 135 137 Total long-term debt, net of current $ 180 $ 289 Total $ 246 $ 355

Note 5 - Share-based Compensa_2

Note 5 - Share-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Options outstanding Weighted average price per share Weighted average remaining life Aggregate intrinsic Value(1) Balance, December 31, 2023 — $ — Granted 3,482,270 $ 0.25 Balance, September 30, 2024 3,482,270 $ 0.25 9.9 $ — Unvested (1,261,982 ) $ 0.24 Vested, September 30, 2024 2,220,288 $ 0.25 9.9 $ — Options outstanding Weighted average price per share Weighted average remaining life Aggregate intrinsic Value(1) Balance, December 31, 2023 41,108,448 $ 0.19 Granted 1,547,938 $ 0.30 Exercised (485,000 ) $ 0.15 Balance, September 30, 2024 42,171,386 $ 0.19 7.0 $ 1,991,000 Unvested (3,623,430 ) $ 0.22 Vested, September 30, 2024 38,547,956 $ 0.19 6.3 $ 1,866,000 Balance, December 31, 2022 28,484,549 $ 0.19 Granted 8,219,920 $ 0.18 Balance, September 30, 2023 36,704,469 $ 0.19 Unvested (4,648,922 ) $ 0.15 Vested Balance, September 30, 2023 32,055,547 $ 0.19 8.0 Options Outstanding Weighted average price per share Weighted average remaining life Aggregate intrinsic Value(1) Balance, December 31, 2023 1,564,085 $ 0.61 Expired (406,585 ) $ 0.61 Vested Balance, September 30, 2024 1,157,500 $ 0.61 1.3 $ — Balance, December 31, 2022 1,904,085 $ 0.56 Expired (340,000 ) $ 0.30 Vested Balance, September 30, 2023 1,564,085 $ 0.61 2.3 Non-plan Options outstanding Weighted average price per share Weighted average remaining life Aggregate intrinsic Value (1) Balance, December 31, 2023 17,375,044 $ 0.39 Granted 85,251 $ 0.23 Expired (865,199 ) $ 0.51 Exercised (463,882 ) $ 0.17 Balance, September 30, 2024 16,131,214 $ 0.39 2.6 $ 130,000 Unvested (437,500 ) $ 0.45 Vested, September 30, 2024 15,693,714 $ 0.39 2.3 $ 130,000 Balance, December 31, 2022 19,023,829 $ 0.39 Granted 60,040 $ 0.20 Expired (1,205,550 ) $ 0.30 Balance, September 30, 2023 17,878,319 $ 0.39 Unvested (507,500 ) $ 0.45 Vested Balance, September 30, 2023 17,370,819 $ 0.39 3.6

Note 6 - Warrants (Tables)

Note 6 - Warrants (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Warrants outstanding Weighted average price per share Weighted average remaining life Aggregate intrinsic value (1) Balance, December 31, 2023 51,590,300 $ 0.27 Granted 4,127,516 $ 0.27 Exercised (3,278,337 ) $ 0.24 Expired (20,534,700 ) $ 0.23 Vested Balance, September 30, 2024 31,904,779 $ 0.29 2.6 $ — Balance, December 31, 2022 49,023,398 $ 0.26 Granted 10,669,896 $ 0.26 Expired (11,313,584 ) $ 0.23 Vested Balance, September 30, 2023 48,379,710 $ 0.27 3.5
Schedule Of Assumptions Used To Determine Fair Value Of Warrants [Table Text Block]	2024 2023 Risk free interest rate 3.69 – 5.38 % 3.88 – 4.27 % Expected volatility 64 – 95 % 40 – 95 % Expected dividend yield — — Forfeiture rate — — Expected life in years .5 – 5 .5 – 5

Note 7 - Accounts Payable and_2

Note 7 - Accounts Payable and Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	Category BioLargo ONM BLEST Canada BETI BEST Intercompany amounts Totals Accounts payable $ 262 $ 1,123 $ 139 $ 39 $ 87 $ — $ (87 ) $ 1,563 Accrued payroll 6 — 37 — — — — 43 Total $ 1,606 Category BioLargo ONM BLEST Canada BETI BEST Intercompany amounts Totals Accounts payable $ 163 $ 964 $ 34 $ 93 40 $ — $ (82 ) $ 1,212 Accrued payroll 49 86 116 — — — — 251 Accrued interest 25 — — — — — — 25 Total $ 1,488

Note 8 - Noncontrolling Inter_2

Note 8 - Noncontrolling Interest - Clyra Medical (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Schedule of Other Ownership Interests [Table Text Block]	Clyra Options Outstanding Weighted average price per share Weighted average remaining life Balance, December 31, 2023 1,478,922 $ 0.31 Granted 72,610 $ 4.18 Vested Balance, September 30, 2024 1,551,532 $ 1.20 6.4 Balance, December 31, 2022 1,583,329 $ 0.06 Granted 85,815 1.46 Exercised (296,389 ) 1.00 Vested Balance, September 30, 2023 1,372,755 $ 0.98 6.1
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2024 2023 Non Plan 2018 Plan 2024 Plan Non Plan 2018 Plan Risk free interest rate 3.81 4.34 % 4.16% 3.75 4.34 % 4.15 % 3.48 4.15 % Expected volatility 95 117 % 99 102 % 95 96 % 112 % 112 114 % Expected dividend yield — — — — — Forfeiture rate — — — — — Life in years 10 10 10 10 10
Warrants Outstanding for Noncontrolling Interest [Table Text Block]	Clyra Options Outstanding Weighted average price per share Weighted average remaining life Balance, December 31, 2023 749,911 $ 3.74 Granted 146,083 $ 7.50 Vested Balance, September 30, 2024 895,994 $ 4.03 2.2 Balance, December 31, 2022 207,513 $ 3.72 Granted 538,898 3.72 Vested Balance, September 30, 2023 746,411 $ 3.72 3.0
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	Category BioLargo ONM BLEST Canada BETI BEST Intercompany amounts Totals Accounts payable $ 262 $ 1,123 $ 139 $ 39 $ 87 $ — $ (87 ) $ 1,563 Accrued payroll 6 — 37 — — — — 43 Total $ 1,606 Category BioLargo ONM BLEST Canada BETI BEST Intercompany amounts Totals Accounts payable $ 163 $ 964 $ 34 $ 93 40 $ — $ (82 ) $ 1,212 Accrued payroll 49 86 116 — — — — 251 Accrued interest 25 — — — — — — 25 Total $ 1,488
Clyra Medical [Member]
Notes Tables
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	September 30, 2024 December 31, 2023 Risk free interest rate 3.95 - 4.34 % 3.48 - 4.45 % Expected volatility 43 - 49 % 40 - 49 % Expected dividend yield — — Forfeiture rate — — Expected life in years 10 10
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	Category 2024 2023 Accounts payable $ 664 $ 135 Accrued dividend 501 $ 242 Accrued payroll 23 7 Accrued interest — 13 Total $ 1,188 $ 397

Note 11 - Business Segment In_2

Note 11 - Business Segment Information (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Revenue ONM Environmental $ 3,853 $ 2,513 $ 12,437 $ 7,374 BLEST 824 843 2,439 1,742 BioLargo Canada — 22 — 31 Clyra Medical — 14 — 20 Intersegment revenue (326 ) (720 ) (754 ) (1,307 ) Total $ 4,351 $ 2,672 $ 14,122 $ 7,860 Stock option expense BioLargo corporate $ (194 ) $ (680 ) $ (1,099 ) $ (1,097 ) Clyra Medical (43 ) (45 ) (165 ) (172 ) Total $ (237 ) $ (725 ) $ (1,264 ) $ (1,269 ) Depreciation expense BioLargo corporate $ (9 ) $ (10 ) $ (28 ) $ (25 ) ONM Environmental (10 ) (5 ) (27 ) (15 ) BLEST (17 ) (28 ) (53 ) (47 ) Clyra Medical (3 ) (3 ) (7 ) (7 ) Total $ (39 ) $ (46 ) $ (115 ) $ (94 ) Research and development expense BioLargo corporate $ (301 ) $ (234 ) $ (838 ) $ (665 ) ONM Environmental — (14 ) — (14 ) BLEST (157 ) (433 ) (845 ) (971 ) BETI (133 ) (537 ) (346 ) (840 ) BioLargo Canada (134 ) (128 ) (311 ) (401 ) Clyra Medical (291 ) (68 ) (512 ) (262 ) Intersegment R&D 326 720 754 1,307 Total $ (690 ) $ (694 ) $ (2,098 ) $ (1,846 ) Operating income (loss) BioLargo corporate $ (798 ) $ (797 ) $ (3,165 ) $ (2,230 ) ONM Environmental 1,382 969 4,668 2,786 BLEST (375 ) (568 ) (1,067 ) (1,388 ) BETI (194 ) (559 ) (575 ) (943 ) BEST (59 ) — (174 ) — BioLargo Canada (160 ) (155 ) (383 ) (549 ) Clyra Medical (857 ) (427 ) (2,019 ) (1,250 ) Total $ (1,061 ) $ (1,537 ) $ (2,715 ) $ (3,574 ) Interest income (expense) BioLargo corporate $ (3 ) $ (3 ) $ (6 ) $ (43 ) ONM Environmental 13 (1 ) 16 (5 ) Clyra Medical (9 ) (8 ) (22 ) (25 ) BioLargo Canada — — — 1 Total $ 1 $ (12 ) $ (12 ) $ (72 ) As of September 30, 2024 BioLargo ONM BLEST CLYRA BETI BEST Canada Elimination Total Tangible assets $ 562 $ 6,376 $ 891 $ 1,440 $ 7 $ — $ 58 $ (63 ) $ 9,271 Right of use operating lease 349 — 670 — — — — — 1,019 Investment in South Korean joint venture 15 — — — — — — — 15 Total $ 926 $ 6,376 $ 1,561 $ 1,440 $ 7 $ — $ 58 $ (63 ) $ 10,305 As of December 31, 2023 BioLargo ONM BLEST CLYRA BETI BEST Canada Elimination Total Tangible assets $ 942 $ 4,624 $ 1,083 $ 432 $ 4 $ — $ 50 $ (41 ) $ 7,094 Right of use operating lease 394 — 698 — — — — — 1,092 Investment in South Korean joint venture 19 — — — — — — — 19 Total $ 1,355 $ 4,624 $ 1,781 $ 432 $ 4 $ — $ 50 $ (41 ) $ 8,205

Note 12 - Leases (Tables)

Note 12 - Leases (Tables)	9 Months Ended
	Sep. 30, 2024
Notes Tables
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]	BioLargo Year ending Corp / ONM BLEST Total December 31, 2024 31,000 39,000 70,000 December 31, 2025 125,000 157,000 282,000 December 31, 2026 129,000 160,000 289,000 December 31, 2027 133,000 163,000 296,000 December 31, 2028 79,000 166,000 245,000 Thereafter — 654,000 654,000 Total minimum lease payments $ 497,000 $ 1,339,000 $ 1,836,000 Less imputed interest (787,000 ) Total operating lease liabilities $ 1,049,000

Note 1 - Business and Organiz_2

Note 1 - Business and Organization (Details Textual)	3 Months Ended						9 Months Ended
	Sep. 30, 2024 USD ($)	Jun. 30, 2024 USD ($)	Mar. 31, 2024 USD ($)	Sep. 30, 2023 USD ($)	Jun. 30, 2023 USD ($)	Mar. 31, 2023 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)	Sep. 30, 2017
Number of Wholly-Owned Subsidiaries	5						5
Number of Partially-Owned Subsidiaries	3						3
Revenue from Contract with Customer, Including Assessed Tax	$ 4,351,000			$ 2,672,000			$ 14,122,000	$ 7,860,000
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	(1,060,000)	$ (780,000)	$ (775,000)	$ (1,508,000)	$ (1,626,000)	$ (494,000)	(2,615,000)	(3,628,000)
Net Cash Provided by (Used in) Operating Activities							(1,290,000)	$ (2,363,000)
Assets, Current	7,394,000						7,394,000		$ 6,362,000
Cash and Cash Equivalents, at Carrying Value	3,882,000						3,882,000		3,539,000
Liabilities, Current	3,200,000						3,200,000		2,710,000
Working Capital (Deficit)	4,194,000						4,194,000
Net Cash Provided by Financing Activities							2,858,000
Conversion of Assets, Contingency, Accounts Receivable to Cash							9
Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised							909,000
Accounts Receivable, after Allowance for Credit Loss, Current	$ 3,209,000						$ 3,209,000		$ 2,612,000
Clyra Medical Technologies [Member]
Subsidiary, Ownership Percentage, Parent	52%						52%
BioLargo Engineering, Science & Technologies, LLC [Member]
Subsidiary, Ownership Percentage, Parent	77.50%						77.50%			100%
BioLargo Energy Technologies, Inc (BETI) [Member]
Subsidiary, Ownership Percentage, Parent	96%						96%

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual)		3 Months Ended		9 Months Ended		12 Months Ended
	Mar. 20, 2020 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($) shares	Sep. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2024 USD ($)	Oct. 22, 2021 USD ($)
Accounts Receivable, Allowance for Credit Loss, Current		$ 97,000		$ 97,000		$ 84,000
Inventory Valuation Reserves		4,000		4,000		4,000
Number of Patents Acquired								3
Income (Loss) from Equity Method Investments		(3,000)	$ (6,000)	$ (4,000)	$ (18,000)
Stock Options and Warrants Vested and Available to be Exercised, Total (in shares) | shares				89,524,237
Contract with Customer, Liability		19,000		$ 19,000		303,000
Contract with Customer, Liability, Revenue Recognized				284,000
Customer Deposit Liability, Current		82,000		82,000		117,000
Revenue Recognized from Customer Deposits				35,000
Unrecognized Tax Benefits		$ 0		$ 0		0
Operating Lease, Weighted Average Discount Rate, Percent		18%		18%
Operating Lease, Right-of-Use Asset		$ 1,019,000		$ 1,019,000		1,092,000
Operating Lease, Liability		1,049,000		1,049,000		1,109,000
ONM [Member]
Customer Deposit Liability, Current		1,000		1,000			$ 4,000
CANADA
Customer Deposit Liability, Current		$ 81,000		$ 81,000		$ 113,000
Odin Co Ltd [Member]
Payments to Acquire Interest in Joint Venture	$ 100,000
Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage	40%			40%
Odin Co Ltd [Member] | Tomorrow Water [Member]
Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage	30%
Odin Co Ltd [Member] | BKT and Tomorrow Water [Member]
Payments to Acquire Interest in Joint Venture	$ 150,000
Clyra Medical Technologies [Member]
Subsidiary, Ownership Percentage, Noncontrolling Owner		48%		48%		47%
BioLargo Engineering, Science & Technologies, LLC [Member]
Subsidiary, Ownership Percentage, Noncontrolling Owner		22.50%		22.50%		22.50%
BioLargo Energy Technologies, Inc (BETI) [Member]
Subsidiary, Ownership Percentage, Noncontrolling Owner		4%		4%		4%
Patents [Member]
Intangible Assets, Net (Excluding Goodwill), Total								$ 34,000
Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)		3 years		3 years
Minimum [Member] | Canadian Government Grants [Member]
Grant Term (Month)		6 months
Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)		10 years		10 years
Maximum [Member] | Canadian Government Grants [Member]
Grant Term (Month)		18 months
Customer Concentration Risk [Member] | Accounts Receivable [Member]
Number of Major Customers				1		1
Customer Concentration Risk [Member] | Accounts Receivable [Member] | One Customer [Member] | Minimum [Member]
Concentration Risk, Percentage				10%		10%

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Summary of Cash Balances (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Cash and Cash Equivalents, at Carrying Value	$ 3,882,000	$ 3,539,000
Parent Company [Member]
Cash and Cash Equivalents, at Carrying Value	3,721,000	3,142,000
Noncontrolling Interest [Member]
Cash and Cash Equivalents, at Carrying Value	$ 161,000	$ 397,000

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Credit Concentration (Details) - Customer A [Member] - Customer Concentration Risk [Member]	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Accounts Receivable [Member]
Credit concentration			79%		68%
Revenue from Contract with Customer Benchmark [Member]
Credit concentration	76%	74%	78%	76%

Note 2 - Summary of Significa_6

Note 2 - Summary of Significant Accounting Policies - Inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Raw material	$ 113	$ 79
Finished goods	125	74
Total	$ 238	$ 153

Note 2 - Summary of Significa_7

Note 2 - Summary of Significant Accounting Policies - Other Non-current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Patents	$ 34	$ 34
Security deposits	36	36
Total	$ 70	$ 70

Note 2 - Summary of Significa_8

Note 2 - Summary of Significant Accounting Policies - Stock Options, Valuation Assumptions (Details)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Non Plan [Member]
Risk free interest rate		4.15%
Expected volatility		112%
Expected dividend yield	0%	0%
Forfeiture rate	0%	0%
Life in years (Year)	10 years	10 years
Non Plan [Member] | Minimum [Member]
Risk free interest rate	3.81%
Expected volatility	95%
Non Plan [Member] | Maximum [Member]
Risk free interest rate	4.34%
Expected volatility	117%
2018 Equity Incentive Plan [Member]
Risk free interest rate	4.16%
Expected dividend yield	0%	0%
Forfeiture rate	0%	0%
Life in years (Year)	10 years	10 years
2018 Equity Incentive Plan [Member] | Minimum [Member]
Risk free interest rate		3.48%
Expected volatility	99%	112%
2018 Equity Incentive Plan [Member] | Maximum [Member]
Risk free interest rate		4.15%
Expected volatility	102%	114%
2024 Equity Incentive Plan [Member]
Expected dividend yield	0%
Forfeiture rate	0%
Life in years (Year)	10 years
2024 Equity Incentive Plan [Member] | Minimum [Member]
Risk free interest rate	3.75%
Expected volatility	95%
2024 Equity Incentive Plan [Member] | Maximum [Member]
Risk free interest rate	4.34%
Expected volatility	96%

Note 3 - Sale of Stock for Ca_2

Note 3 - Sale of Stock for Cash (Details Textual)	3 Months Ended		9 Months Ended
	Sep. 30, 2024 shares	Sep. 30, 2023 USD ($) shares	Sep. 30, 2024 USD ($) shares	Sep. 30, 2023 USD ($) shares	Dec. 13, 2022 USD ($)
Proceeds from Issuance of Common Stock			$ 609,000	$ 1,497,000
Warrants Issued with 2020 Unit Offering [Member] | Minimum [Member]
Warrants and Rights Outstanding, Term (Year)	6 years	6 months	6 years	6 months
Warrants Issued with 2020 Unit Offering [Member] | Maximum [Member]
Warrants and Rights Outstanding, Term (Year)	5 years	5 years	5 years	5 years
The 2020 Unit Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares		0		5,234,948
Proceeds From Issuance of Common Stock, Gross				$ 995,000
The 2020 Unit Offering [Member] | Issuance to Seven Accredited Investors [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares	0		1,848,720
Proceeds From Issuance of Common Stock, Gross			$ 419,000
Proceeds from Issuance of Common Stock			$ 349,000
Number of Accredited Investors	7		7
Lincoln Park Capital Fund, LLC [Member]
Stock Purchase Agreement, Maximum Amount of Common Stock					$ 10,000,000
Stock Issued During Period, Shares, New Issues (in shares) | shares	0	1,190,223	766,175	2,833,846
Proceeds From Issuance of Common Stock, Gross		$ 203,000	$ 260,000	$ 502,000
Proceeds from Issuance of Common Stock			$ 260

Note 4 - Debt Obligations (Deta

Note 4 - Debt Obligations (Details Textual) - USD ($)				1 Months Ended	3 Months Ended		9 Months Ended
	Jun. 28, 2024	Feb. 07, 2023	Feb. 07, 2022	Jul. 31, 2020	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Interest Income (Expense), Nonoperating					$ 1,000	$ (12,000)	$ (12,000)	$ (72,000)
Interest Expense, Debt						$ 12,000		$ 72,000
Paycheck Protection Program CARES Act [Member] | BLEST [Member]
Extinguishment of Debt, Amount	$ 97,000
Paycheck Protection Program CARES Act [Member] | ONM [Member]
Extinguishment of Debt, Amount			$ 174,000
Proceeds from Issuance of Debt			$ 217,000
Long-Term Debt					43,000		43,000
Economic Injury Disaster Loan [Member] | ONM [Member]
Debt Instrument, Face Amount				$ 150,000
Debt Instrument, Interest Rate, Stated Percentage				3.75%
Debt Instrument, Periodic Payment				$ 700
Debt Instrument, Outstanding Balance					145,000		145,000
Vehicle Loan [Member]
Debt Instrument, Face Amount		$ 80,000
Debt Instrument, Interest Rate, Stated Percentage		5.29%
Debt Instrument, Periodic Payment		$ 1,000
Debt Instrument, Outstanding Balance					$ 58,000		$ 58,000

Note 4 - Debt Obligations - Sch

Note 4 - Debt Obligations - Schedule of Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Total current portion of debt	$ 66	$ 66
Total long-term debt, net of current	180	289
Total	246	355
Vehicle Loan [Member]
Long-term debt, current	13	13
Total long-term debt, net of current	45	55
Paycheck Protection Program CARES Act [Member]
SBA Paycheck Protection Program loan	43	43
SBA Paycheck Protection Program loans, matures May 2025	0	97
Economic Injury Disaster Loan [Member]
Long-term debt, current	10	10
Total long-term debt, net of current	$ 135	$ 137

Note 5 - Share-based Compensa_3

Note 5 - Share-based Compensation (Details Textual) - USD ($)								3 Months Ended						9 Months Ended
	Sep. 30, 2024	Aug. 13, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Jun. 22, 2018	Sep. 07, 2017	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Stock Issued During Period, Value, Issued for Services								$ 63,000	$ 116,000	$ 83,000	$ 37,000	$ 75,000	$ 207,000
Share Price (in dollars per share)	$ 0.23							$ 0.23						$ 0.23
Proceeds from Stock Options Exercised														$ 153,000	$ 0
2024 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)														10 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Per Year (in shares)														2
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)	50,000,000							50,000,000						50,000,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)	46,517,730							46,517,730						46,517,730
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)														3,482,270
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)														$ 0.25
2018 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)						10 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Per Year (in shares)						2,000,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)	9,343,614							9,343,614						9,343,614
Share Price (in dollars per share)	$ 0.23							$ 0.23						$ 0.23
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)														1,547,938	8,219,920
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	$ 626,000							$ 626,000						$ 626,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)														4 years
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)														$ 0.3	$ 0.18
Equity Incentive Plan 2007 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)							10 years
Share Price (in dollars per share)	$ 0.23							$ 0.23						0.23
Non Plan [Member]
Share Price (in dollars per share)	$ 0.23							$ 0.23						$ 0.23
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)														85,251	60,040
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)														$ 0.23	$ 0.2
Share-Based Payment Arrangement, Option [Member]
Share-Based Payment Arrangement, Expense								$ 43,000			45,000			$ 165,000	$ 172,000
Share-Based Payment Arrangement, Option [Member] | 2024 Equity Incentive Plan [Member]
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	$ 276,000							276,000						$ 276,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)														4 years
Selling, General and Administrative Expenses [Member]
Share-Based Payment Arrangement, Expense								$ 237,000			$ 725,000			$ 1,264,000	$ 1,269,000
Officer [Member]
Stock Issued During Period, Value, Issued for Services	$ 9,000		$ 12,000	$ 12,000	$ 6,000
Stock Issued During Period, Shares, Issued for Services (in shares)	41,087		69,563	68,541	30,747				0	0
Shares Issued, Price Per Share (in dollars per share)	$ 0.23		$ 0.17	$ 0.18	$ 0.2			$ 0.23			$ 0.17	$ 0.18	$ 0.2	$ 0.23	$ 0.17
Consultants [Member]
Stock Issued During Period, Value, Issued for Services								$ 54,000	$ 116,000	$ 83,000	$ 25,000	$ 63,000	$ 201,000
Stock Issued During Period, Shares, Issued for Services (in shares)								219,816	446,989	288,997	146,123	352,370	899,743
Shares Issued, Price Per Share (in dollars per share)	$ 0.23		$ 0.17	$ 0.18	$ 0.2			$ 0.23	$ 0.26	$ 0.35	$ 0.17	$ 0.18	$ 0.2	$ 0.23	$ 0.17
Consultants [Member] | 2024 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)														697,616
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value														$ 223,000
Board of Directors, Employees, and Consultants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)														1,547,938
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value														$ 418,000
Board of Directors, Employees, and Consultants [Member] | 2024 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)														3,482,270
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value														$ 782,000
Board of Directors, Employees, and Consultants [Member] | 2018 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)														544,841
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value														$ 173,000
Board Of Directors [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)														267,746
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value														$ 85,000
Board Of Directors [Member] | 2024 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)														771,180
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value														$ 171,000
Board Of Directors [Member] | 2018 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)															1,565,858
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value															$ 266,000
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)											$ 0.17	$ 0.18	$ 0.2
Employees [Member] | Employee Retention Program [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)															1,784,140
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value															$ 306,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)															4 years
Employees [Member] | Employee Retention Program [Member] | 2024 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)														1,013,474
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value														$ 154,000
Employees [Member] | Employee Retention Program [Member] | 2018 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)														735,351
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value														$ 160,000
Chief Financial Officer [Member] | 2024 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)														1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value														$ 234,000
Chief Financial Officer [Member] | 2018 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)															800,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value															$ 141,000
Chief Financial Officer [Member] | Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)		10 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)		300,000
Engagement Extension, Term (Year)		1 year
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross, Per Month (in shares)		25,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price (in dollars per share)		$ 0.24
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Available Grants in Period, Gross, Upon Renewal (in shares)		300,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vesting Period for Renewable Options (Year)		1 year
Chief Financial Officer [Member] | Share-Based Payment Arrangement, Option [Member] | 2018 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)															500,000
Officer, Board of Directors, Employees, and a Consultant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)															8,219,920
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value															$ 1,370,000
Employees and Consultants [Member] | 2018 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)															4,069,922
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)															$ 657,000
Vendors [Member] | Non Plan [Member]
Share-Based Payment Arrangement, Expense														$ 18,000	$ 11,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)														85,251	60,040
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)															$ 0.2
Remaining Stock Option Plan Expense	$ 109,000							$ 109,000						$ 109,000
Investors [Member] | Share-Based Payment Arrangement, Option [Member] | Non Plan [Member]
Proceeds from Stock Options Exercised														$ 153,000
Stock Issued During Period, Shares, New Issues (in shares)														463,882

Note 5 - Share-based Compensa_4

Note 5 - Share-based Compensation - Stock Options (Details) - USD ($)		9 Months Ended
		Sep. 30, 2024	Sep. 30, 2023
2024 Equity Incentive Plan [Member]
Options outstanding, balance (in shares)		0
Weighted average exercise price, balance (in dollars per share)		$ 0
Options outstanding, Granted (in shares)		3,482,270
Weighted average exercise price, Granted (in dollars per share)		$ 0.25
Weighted average remaining term, Outstanding (Year)		9 years 10 months 24 days
Aggregate intrinsic Value, Balance	[1]	$ 0
Unvested (in shares)		(1,261,982)
Weighted average exercise price per share, unvested (in dollars per share)		$ 0.24
Options outstanding, Vested (in shares)		2,220,288
Weighted average exercise price, Vested (in dollars per share)		$ 0.25
Weighted average remaining term, Vested (Year)		9 years 10 months 24 days
Aggregate intrinsic value, Vested	[1]	$ 0
Options outstanding, balance (in shares)		3,482,270
Weighted average exercise price, balance (in dollars per share)		$ 0.25
Vested Balance (in shares)		2,220,288
Vested Balance, Weighted Average Exercise Price (in dollars per share)		$ 0.25
2018 Equity Incentive Plan [Member]
Options outstanding, balance (in shares)		41,108,448	28,484,549
Weighted average exercise price, balance (in dollars per share)		$ 0.19	$ 0.19
Options outstanding, Granted (in shares)		1,547,938	8,219,920
Weighted average exercise price, Granted (in dollars per share)		$ 0.3	$ 0.18
Weighted average remaining term, Outstanding (Year)		7 years
Aggregate intrinsic Value, Balance	[2]	$ 1,991,000
Unvested (in shares)		(3,623,430)	(4,648,922)
Weighted average exercise price per share, unvested (in dollars per share)		$ 0.22	$ 0.15
Options outstanding, Vested (in shares)		38,547,956	32,055,547
Weighted average exercise price, Vested (in dollars per share)		$ 0.19	$ 0.19
Weighted average remaining term, Vested (Year)		6 years 3 months 18 days	8 years
Aggregate intrinsic value, Vested	[2]	$ 1,866,000
Options Outstanding, Exercised (in shares)		(485,000)
Weighted average exercise price, Exercised (in dollars per share)		$ 0.15
Options outstanding, balance (in shares)		42,171,386	36,704,469
Weighted average exercise price, balance (in dollars per share)		$ 0.19	$ 0.19
Vested Balance (in shares)		38,547,956	32,055,547
Vested Balance, Weighted Average Exercise Price (in dollars per share)		$ 0.19	$ 0.19
The 2007 Equity Incentive Plan [Member]
Options outstanding, balance (in shares)		1,564,085	1,904,085
Weighted average exercise price, balance (in dollars per share)		$ 0.61	$ 0.56
Options outstanding, Vested (in shares)		1,157,500	1,564,085
Weighted average exercise price, Vested (in dollars per share)		$ 0.61	$ 0.61
Weighted average remaining term, Vested (Year)		1 year 3 months 18 days	2 years 3 months 18 days
Aggregate intrinsic value, Vested	[2]	$ 0
Options outstanding, Expired (in shares)		(406,585)	(340,000)
Weighted average exercise price per share, Expired (in dollars per share)		$ 0.61
Vested Balance (in shares)		1,157,500	1,564,085
Vested Balance, Weighted Average Exercise Price (in dollars per share)		$ 0.61	$ 0.61
The 2007 Equity Incentive Plan [Member] | Minimum [Member]
Weighted average exercise price per share, Expired (in dollars per share)			$ 0.3
Non Plan [Member]
Options outstanding, balance (in shares)		17,375,044	19,023,829
Weighted average exercise price, balance (in dollars per share)		$ 0.39	$ 0.39
Options outstanding, Granted (in shares)		85,251	60,040
Weighted average exercise price, Granted (in dollars per share)		$ 0.23	$ 0.2
Weighted average remaining term, Outstanding (Year)		2 years 7 months 6 days
Unvested (in shares)		(437,500)	(507,500)
Weighted average exercise price per share, unvested (in dollars per share)		$ 0.45	$ 0.45
Options outstanding, Vested (in shares)		15,693,714	17,370,819
Weighted average exercise price, Vested (in dollars per share)		$ 0.39	$ 0.39
Weighted average remaining term, Vested (Year)		2 years 3 months 18 days	3 years 7 months 6 days
Aggregate intrinsic value, Vested	[2]	$ 130,000
Options Outstanding, Exercised (in shares)		(865,199)	(1,205,550)
Weighted average exercise price, Exercised (in dollars per share)		$ 0.51	$ 0.3
Options outstanding, balance (in shares)		16,131,214	17,878,319
Weighted average exercise price, balance (in dollars per share)		$ 0.39	$ 0.39
Options outstanding, Expired (in shares)		(463,882)
Weighted average exercise price per share, Expired (in dollars per share)		$ 0.17
Vested Balance (in shares)		15,693,714	17,370,819
Vested Balance, Weighted Average Exercise Price (in dollars per share)		$ 0.39	$ 0.39
Aggregate intrinsic value, balance	[2]	$ 130,000
[1]Aggregate intrinsic value based on closing common stock price of $0.23 at September 30, 2024.[2]Aggregate intrinsic value based on closing common stock price of $0.23 and $0.17 at September 30, 2024 and 2023.

Note 6 - Warrants (Details Text

Note 6 - Warrants (Details Textual) - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Mar. 06, 2023
Share Price (in dollars per share)	$ 0.23
Proceeds from Warrant Exercises	$ 756,000	$ 0
Warrants and Rights Outstanding	$ 0
Note Payable, Maturing March 8, 2023 [Member]
Debt Instrument, Face Amount			$ 50,000
Six-month Warrants in Connection With the 2020 Unit Offering [Member]
Warrants and Rights Outstanding, Term (Year)	6 months	6 months
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	454,547	5,234,948
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.33	$ 0.23
Five Year Warrants in Connection with the 2020 Unit Offering, Commissions [Member]
Warrants and Rights Outstanding, Term (Year)	5 years
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	454,547
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.33
Warrants and Rights Outstanding, Fair Value	$ 160,000
Five-month Warrants in Connection With the 2020 Unit Offering [Member]
Warrants and Rights Outstanding, Term (Year)		5 years
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)		5,234,948
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.29
Warrants and Rights Outstanding, Fair Value		$ 913,000
Warrants Issued in Connection with Conversion of Interest on Note Payable Maturing March 8, 2023 [Member]
Warrants and Rights Outstanding, Term (Year)			5 years
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)			200,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 0.21
Warrants and Rights Outstanding			$ 30,000
Investors [Member]
Stock Issued During Period, Shares, Exercise of Warrants (in shares)	3,278,337
Proceeds from Warrant Exercises	$ 756,000

Note 6 - Warrants - Warrants Ou

Note 6 - Warrants - Warrants Outstanding (Details) - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Warrants outstanding, balance (in shares)	51,590,300	49,023,398
Warrants outstanding, Granted (in shares)	4,127,516	10,669,896
Warrants outstanding, Exercised (in shares)	(3,278,337)
Warrants outstanding, Expired (in shares)	(20,534,700)	(11,313,584)
Warrants outstanding, balance (in shares)	31,904,779	48,379,710
Weighted Average Remaining Life, Balance (Year)	2 years 7 months 6 days	3 years 6 months
Warrants and Rights Outstanding	$ 0
Weighted Average [Member]
Weighted average price, balance (in dollars per share)	$ 0.27	$ 0.26
Weighted average price, Granted (in dollars per share)	0.27	0.26
Weighted average price, Exercised (in dollars per share)	0.24
Weighted average price, Expired (in dollars per share)	0.23	0.23
Weighted average price, balance (in dollars per share)	0.29	0.27
Weighted average price, balance (in dollars per share)	$ 0.29	$ 0.27

Note 6 - Warrants - Assumptions

Note 6 - Warrants - Assumptions Used to Determine Fair Value of Warrants (Details)	Sep. 30, 2024	Dec. 31, 2023
Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Risk free interest rate	0.0369	0.0388
Minimum [Member] | Measurement Input, Price Volatility [Member]
Risk free interest rate	0.64	0.40
Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Risk free interest rate	0.0538	0.0427
Maximum [Member] | Measurement Input, Price Volatility [Member]
Risk free interest rate	0.95	0.95

Note 7 - Accounts Payable and_3

Note 7 - Accounts Payable and Accrued Expenses - Summary of Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Accounts payable	$ 1,563	$ 1,212
Accrued payroll	43	251
Total	1,606	1,488
Accrued interest		25
Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]
Accounts payable	262	163
Accrued payroll	6	49
Accrued interest		25
Operating Segments [Member] | Odor-No-More [Member]
Accounts payable	1,123	964
Accrued payroll	0	86
Accrued interest		0
Operating Segments [Member] | BLEST [Member]
Accounts payable	139	34
Accrued payroll	37	116
Accrued interest		0
Operating Segments [Member] | BioLargo Canada [Member]
Accounts payable	39	93
Accrued payroll	0	0
Accrued interest		0
Operating Segments [Member] | BioLargo Energy Technologies, Inc (BETI) [Member]
Accounts payable	87	40
Accrued payroll	0	0
Accrued interest		0
Operating Segments [Member] | BEST [Member]
Accounts payable	0	0
Accrued payroll	0	0
Accrued interest		0
Consolidation, Eliminations [Member]
Accounts payable	(87)	(82)
Accrued payroll	$ 0	0
Accrued interest		$ 0

Note 8 - Noncontrolling Inter_3

Note 8 - Noncontrolling Interest - Clyra Medical (Details Textual)			1 Months Ended			3 Months Ended						9 Months Ended		12 Months Ended
	Dec. 15, 2023	Jun. 30, 2020 USD ($) shares	Jul. 31, 2024 USD ($) shares	Jun. 30, 2024 USD ($) shares	Jan. 31, 2023 shares	Sep. 30, 2024 USD ($) $ / shares shares	Jun. 30, 2024 USD ($) shares	Mar. 31, 2024 USD ($) $ / shares shares	Sep. 30, 2023 USD ($) $ / shares	Jun. 30, 2023 USD ($)	Mar. 31, 2023 USD ($)	Sep. 30, 2024 USD ($) $ / shares shares	Sep. 30, 2023 USD ($) $ / shares shares	Dec. 31, 2023 USD ($) shares	Apr. 08, 2022 USD ($)
Debt Conversion, Original Debt, Amount												$ 84,000	$ 1,860,000
Long-Term Line of Credit						$ 134,000						134,000
Line of Credit Facility, Interest Rate During Period						15%
Stock Issued During Period, Value, New Issues						$ 15,000	$ 136,000	$ 488,000	$ 203,000	$ 494,000	$ 800,000
Research and Development Expense						$ 690,000			694,000			$ 2,098,000	1,846,000
Common Stock, Shares, Issued (in shares) | shares						301,163,538						301,163,538		292,945,747
Warrants and Rights Outstanding						$ 0						$ 0
Share Price (in dollars per share) | $ / shares						$ 0.23						$ 0.23
Share-Based Payment Arrangement, Option [Member]
Share-Based Payment Arrangement, Expense						$ 43,000			$ 45,000			$ 165,000	$ 172,000
Clyra Medical [Member] | Common Stock [Member]
Investment Owned, Balance, Shares (in shares) | shares						5,471,156						5,471,156		5,322,775
Clyra Medical [Member] | Preferred Stock, Series A [Member]
Investment Owned, Balance, Shares (in shares) | shares						165,765						165,765
Clyra Medical [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	100
Stock Issued During Period, Shares, New Issues (in shares) | shares						2,730	2,730	27,600					0
Stock Issued During Period, Value, New Issues						$ 37,000	$ 14,000
Shares Issued, Price Per Share (in dollars per share) | $ / shares								$ 2.71
Research and Development Expense												$ 52,000
Stock Issued, Discount on Fair Value, Percentage												30%
Shares, Outstanding (in shares) | shares						10,452,377						10,452,377		10,000,749
Common Stock, Shares, Issued (in shares) | shares						297,397						297,397
Preferred Stock Dividends and Other Adjustments												$ 503,000		$ 241,000
Clyra Medical [Member] | Share-Based Payment Arrangement, Option [Member] | Employees and Consultants [Member]
Share-Based Payment Arrangement, Expense												$ 131,000	$ 172,000
Share Price (in dollars per share) | $ / shares						$ 4.5			$ 2.71			$ 4.5	$ 2.71
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount Rate												30%
Clyra Medical [Member] | Vendors [Member]
Proceeds from Issuance or Sale of Equity												$ 1,290,000
Clyra Medical [Member] | Warrants Expiring February 28, 2027 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares						146,083						146,083
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares						$ 7.5						$ 7.5
Number of Accredited Investors						5						5
Clyra Medical [Member] | Warrants Issued in Conjunction With the Sale of Series A Preferred Stock [Member]
Shares Issued, Price Per Share (in dollars per share) | $ / shares						$ 3.72						$ 3.72
Warrants and Rights Outstanding						$ 524,000						$ 524,000
Clyra Medical [Member] | Clyra Unit Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares						146,083						146,083
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares						$ 7.5						$ 7.5
Warrants and Rights Outstanding						$ 156,000						$ 156,000
Share Price (in dollars per share) | $ / shares						$ 4.5			$ 2.71			$ 4.5	$ 2.71
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount Rate												30%
Warrants and Rights Outstanding, Term (Year)						3 years						3 years
Clyra Medical [Member] | Series A Preferred Stock [Member]
Shares Issued, Price Per Share (in dollars per share) | $ / shares						$ 3.1						$ 3.1
Shares, Outstanding (in shares) | shares						746,418						746,418		746,418
Preferred Stock, Dividend Rate, Percentage												15%
Preferred Stock, Convertible, Sale of Stock Amount						$ 5,000,000						$ 5,000,000
Clyra Medical [Member] | Preferred Class A [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares												746,618
Proceeds from Issuance of Preferred Stock and Preference Stock												$ 1,800,000
Clyra Medical [Member] | Revolving Credit Facility [Member] | Vernal Bay Capital Group, LLC [Member] | Inventory Line of Credit [Member]
Line of Credit Facility, Maximum Borrowing Capacity		$ 1,000,000
Proceeds from Lines of Credit, Total		$ 260,000
Repayments of Lines of Credit								$ 126,000
Stock Issued During Period, Shares, Commitment Fee (in shares) | shares		32,200
Stock Issued During Period, Value, Commitment Fee		$ 70,000
Debt Instrument, Percentage of Principal Payment, Cap														15%
Clyra Medical [Member] | Shares Issued For Conversion of Notes Payable [Member]
Debt Conversion, Original Debt, Amount			$ 119,000
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares			34,126
Clyra Medical [Member] | Preferred Shares Issued for Debt Owed to Biolargo [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares				148,156
Debt Conversion, Converted Instrument, Amount				$ 741,000
Clyra Medical [Member] | Notes Payable, Other Payables [Member]
Debt Instrument, Face Amount															$ 100,000
Debt Instrument, Interest Rate, Stated Percentage															8%
Debt Instrument, Convertible, Sale of Stock Amount															$ 5,000,000
Debt Instrument, Convertible, Conversion Percentage															70%
Vernal Bay Capital Group, LLC [Member] | Conversion of Clyra Medical Stock Into Biolargo Common Stock [Member]
Stock Issued During Period, Shares, Commitment Fee (in shares) | shares					32,200
Conversion of Stock, Shares Issued (in shares) | shares					527,983

Note 8 - Noncontrolling Inter_4

Note 8 - Noncontrolling Interest - Clyra Medical - Common Shares Outstanding (Details) - Clyra Medical [Member] - $ / shares	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Clyra options outstanding, balance (in shares)	1,478,922	1,583,329
Weighted average price, balance (in dollars per share)	$ 0.31	$ 0.06
Options outstanding, Granted (in shares)	72,610	85,815
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)	$ 4.18	$ 1.46
Vested Balance (in shares)	1,551,532	1,372,755
Vested Balance, Weighted Average Exercise Price (in dollars per share)	$ 1.2	$ 0.98
Weighted average remaining term, Outstanding (Year)	6 years 4 months 24 days	6 years 1 month 6 days
Options Outstanding, Exercised (in shares)		(296,389)
Weighted average exercise price, Exercised (in dollars per share)		$ 1

Note 8 - Noncontrolling Inter_5

Note 8 - Noncontrolling Interest - Clyra Medical - Valuation Assumptions (Details)	9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Clyra Medical [Member] | Vendors and Employees [Member]
Expected volatility	49%
Life in years (Year)	10 years		10 years
Minimum [Member] | Clyra Medical [Member] | Vendors and Employees [Member]
Risk free interest rate			3.48%
Expected volatility			40%
Maximum [Member] | Clyra Medical [Member] | Vendors and Employees [Member]
Risk free interest rate	4.34%		4.45%
Expected volatility			49%
Non Plan [Member]
Risk free interest rate		4.15%
Expected volatility		112%
Life in years (Year)	10 years	10 years
Non Plan [Member] | Clyra Medical [Member] | Vendors and Employees [Member]
Expected volatility	43%
Non Plan [Member] | Minimum [Member]
Risk free interest rate	3.81%
Expected volatility	95%
Non Plan [Member] | Minimum [Member] | Clyra Medical [Member] | Vendors and Employees [Member]
Risk free interest rate	3.95%
Non Plan [Member] | Maximum [Member]
Risk free interest rate	4.34%
Expected volatility	117%

Note 8 - Noncontrolling Inter_6

Note 8 - Noncontrolling Interest - Clyra Medical - Warrants Outstanding (Details) - $ / shares	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Warrants outstanding, balance (in shares)	51,590,300	49,023,398
Warrants outstanding, balance (in shares)	31,904,779	48,379,710
Weighted Average Remaining Life, Balance (Year)	2 years 7 months 6 days	3 years 6 months
Clyra Medical [Member]
Warrants outstanding, balance (in shares)	749,911	207,513
Granted Warrants, Balance (in shares)	146,083	538,898
Warrants outstanding, balance (in shares)	895,994	746,411
Weighted Average Remaining Life, Balance (Year)	2 years 2 months 12 days	3 years
Clyra Medical [Member] | Minimum [Member]
Outstanding Warrants, Weighted Average Price Per Share (in dollars per share)	$ 3.74	$ 3.72
Granted Warrants, Weighted Average Price Per Share (in dollars per share)	7.5	3.72
Outstanding Warrants, Weighted Average Price Per Share (in dollars per share)	$ 4.03	$ 3.72

Note 8 - Noncontrolling Inter_7

Note 8 - Noncontrolling Interest - Clyra Medical - Summary of Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Accounts payable	$ 1,563	$ 1,212
Accrued payroll	43	251
Accrued interest		25
Accounts payable and accrued expenses, total	1,606	1,488
Clyra Medical [Member]
Accounts payable	664	135
Accrued dividend	501	242
Accrued payroll	23	7
Accrued interest	0	13
Accounts payable and accrued expenses, total	$ 1,188	$ 397

Note 9 - BioLargo Engineering_2

Note 9 - BioLargo Engineering, Science and Technologies, LLC (Details Textual) - shares	1 Months Ended
	Sep. 30, 2017	Sep. 30, 2024	Dec. 31, 2023
Seven Employees Working at BioLargo Engineering, Science & Technologies, LLC [Member]
Percentage of Profits Interests Vested		22.50%	22.50%
Seven Employees Working at BioLargo Engineering, Science & Technologies, LLC [Member] | Non-Qualified Stock Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)	1,750,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)	5 years
BioLargo Engineering, Science & Technologies, LLC [Member]
Subsidiary, Ownership Percentage, Parent	100%	77.50%

Note 10 - BioLargo Energy Tec_2

Note 10 - BioLargo Energy Technologies, Inc. (Details Textual)	3 Months Ended	6 Months Ended	9 Months Ended
	Sep. 30, 2023 USD ($) shares	Sep. 30, 2024 USD ($) $ / shares shares	Sep. 30, 2024 $ / shares shares	Sep. 30, 2023 USD ($) shares
Share Price (in dollars per share) | $ / shares		$ 0.23	$ 0.23
BioLargo Energy Technologies, Inc (BETI) [Member]
Investment Owned, Balance, Shares (in shares)		9,100,000	9,100,000
BioLargo Energy Technologies, Inc (BETI) [Member]
Investment Owned, Balance, Shares (in shares)		9,000,000	9,000,000
Stock Issued During Period, Shares, New Issues (in shares)	10,000	20,000		467,000
Share Price (in dollars per share) | $ / shares		$ 2.5	$ 2.5
Number of Accredited Investors		1	1
Proceeds from Issuance or Sale of Equity | $	$ 25,000	$ 50,000		$ 1,005,000
Stock Conversion, Discount on Volume Weighted Average Price	20%	20%	20%	20%
Shares, Outstanding (in shares)		9,487,000	9,487,000
BioLargo Energy Technologies, Inc (BETI) [Member] | Biolargo [Member]
Proceeds from Issuance or Sale of Equity | $				$ 100,000
Biolargo [Member] | Conversion Debt to Equity [Member]
Conversion of Stock, Shares Converted (in shares)			50,000
Conversion of Stock, Shares Issued (in shares)			378,788

Note 11 - Business Segment In_3

Note 11 - Business Segment Information (Details Textual)	3 Months Ended
	Sep. 30, 2024
Number of Operating Segments	6

Note 11 - Business Segment In_4

Note 11 - Business Segment Information - Segment Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Revenue from Contract with Customer, Including Assessed Tax	$ 4,351,000	$ 2,672,000	$ 14,122,000	$ 7,860,000
Stock option expense	(237,000)	(725,000)	(1,264,000)	(1,269,000)
Depreciation	(39,000)	(46,000)	(115,000)	(94,000)
Research and Development Expense	(690,000)	(694,000)	(2,098,000)	(1,846,000)
Operating income (loss)	(1,061,000)	(1,537,000)	(2,715,000)	(3,574,000)
Interest income (expense)	1,000	(12,000)	(12,000)	(72,000)
Tangible assets	9,271,000		9,271,000		$ 7,094,000
Right of use, operating leases, net of amortization	1,019,000		1,019,000		1,092,000
Investment in South Korean joint venture	15,000		15,000		19,000
Total	10,305,000		10,305,000		8,205,000
Investment in South Korean Joint Venture [Member]
Investment in South Korean joint venture	15,000		15,000		19,000
Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]
Stock option expense	(194,000)	(680,000)	(1,099,000)	(1,097,000)
Depreciation	(9,000)	(10,000)	(28,000)	(25,000)
Research and Development Expense	(301,000)	(234,000)	(838,000)	(665,000)
Operating income (loss)	(798,000)	(797,000)	(3,165,000)	(2,230,000)
Interest income (expense)	(3,000)	(3,000)	(6,000)	(43,000)
Tangible assets	562,000		562,000		942,000
Right of use, operating leases, net of amortization	349,000		349,000		394,000
Total	926,000		926,000		1,355,000
Segment Reporting, Reconciling Item, Corporate Nonsegment [Member] | Investment in South Korean Joint Venture [Member]
Investment in South Korean joint venture	15,000		15,000		19,000
Operating Segments [Member] | Odor-No-More [Member]
Revenue from Contract with Customer, Including Assessed Tax	3,853,000	2,513,000	12,437,000	7,374,000
Depreciation	(10,000)	(5,000)	(27,000)	(15,000)
Research and Development Expense	0	(14,000)	0	(14,000)
Operating income (loss)	1,382,000	969,000	4,668,000	2,786,000
Interest income (expense)	13,000	(1,000)	16,000	(5,000)
Tangible assets	6,376,000		6,376,000		4,624,000
Right of use, operating leases, net of amortization	0		0		0
Total	6,376,000		6,376,000		4,624,000
Operating Segments [Member] | Odor-No-More [Member] | Investment in South Korean Joint Venture [Member]
Investment in South Korean joint venture	0		0		0
Operating Segments [Member] | BLEST [Member]
Tangible assets	891,000		891,000		1,083,000
Right of use, operating leases, net of amortization	670,000		670,000		698,000
Total	1,561,000		1,561,000		1,781,000
Operating Segments [Member] | BLEST [Member] | Investment in South Korean Joint Venture [Member]
Investment in South Korean joint venture	0		0		0
Operating Segments [Member] | Clyra Medical [Member]
Tangible assets	1,440,000		1,440,000		432,000
Right of use, operating leases, net of amortization	0		0		0
Total	1,440,000		1,440,000		432,000
Operating Segments [Member] | Clyra Medical [Member] | Investment in South Korean Joint Venture [Member]
Investment in South Korean joint venture	0		0		0
Operating Segments [Member] | BioLargo Energy Technologies, Inc (BETI) [Member]
Research and Development Expense	(133,000)	(537,000)	(346,000)	(840,000)
Operating income (loss)	(194,000)	(559,000)	(575,000)	(943,000)
Tangible assets	7,000		7,000		4,000
Right of use, operating leases, net of amortization	0		0		0
Total	7,000		7,000		4,000
Operating Segments [Member] | BioLargo Energy Technologies, Inc (BETI) [Member] | Investment in South Korean Joint Venture [Member]
Investment in South Korean joint venture	0		0		0
Operating Segments [Member] | BEST [Member]
Operating income (loss)	(59,000)	0	(174,000)	0
Tangible assets	0		0		0
Right of use, operating leases, net of amortization	0		0		0
Total	0		0		0
Operating Segments [Member] | BEST [Member] | Investment in South Korean Joint Venture [Member]
Investment in South Korean joint venture	0		0		0
Operating Segments [Member] | BioLargo Canada [Member]
Revenue from Contract with Customer, Including Assessed Tax	0	22,000	0	31,000
Research and Development Expense	(134,000)	(128,000)	(311,000)	(401,000)
Operating income (loss)	(160,000)	(155,000)	(383,000)	(549,000)
Interest income (expense)	0	0	0	1
Tangible assets	58,000		58,000		50,000
Right of use, operating leases, net of amortization	0		0		0
Total	58,000		58,000		50,000
Operating Segments [Member] | BioLargo Canada [Member] | Investment in South Korean Joint Venture [Member]
Investment in South Korean joint venture	0		0		0
Operating Segments [Member] | BioLargo Engineering, Science & Technologies, LLC [Member]
Revenue from Contract with Customer, Including Assessed Tax	824,000	843,000	2,439,000	1,742,000
Depreciation	(17,000)	(28,000)	(53,000)	(47,000)
Research and Development Expense	(157,000)	(433,000)	(845,000)	(971,000)
Operating income (loss)	(375,000)	(568,000)	(1,067,000)	(1,388,000)
Operating Segments [Member] | Clyra Segment [Member]
Revenue from Contract with Customer, Including Assessed Tax	0	14,000	0	20,000
Stock option expense	(43,000)	(45,000)	(165,000)	(172,000)
Depreciation	(3,000)	(3,000)	(7,000)	(7,000)
Research and Development Expense	(291,000)	(68,000)	(512,000)	(262,000)
Operating income (loss)	(857,000)	(427,000)	(2,019,000)	(1,250,000)
Interest income (expense)	(9,000)	(8,000)	(22,000)	(25,000)
Consolidation, Eliminations [Member]
Revenue from Contract with Customer, Including Assessed Tax	(326,000)	(720,000)	(754,000)	(1,307,000)
Research and Development Expense	326,000	$ 720,000	754,000	$ 1,307,000
Tangible assets	(63,000)		(63,000)		(41,000)
Right of use, operating leases, net of amortization	0		0		0
Total	(63,000)		(63,000)		(41,000)
Consolidation, Eliminations [Member] | Investment in South Korean Joint Venture [Member]
Investment in South Korean joint venture	$ 0		$ 0		$ 0

Note 12 - Leases (Details Textu

Note 12 - Leases (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Operating Lease, Expense	$ 92,000	$ 88,000	$ 268,000	$ 254,000
Lessee, Operating Lease, Discount Rate	18%		18%
Operating Lease, Weighted Average Remaining Lease Term (Year)	7 years		7 years
Lessee, Operating Lease, Liability, to be Paid	$ 1,836,000		$ 1,836,000

Note 12 - Leases - Schedule of

Note 12 - Leases - Schedule of Future Minimum Lease Payments (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
December 31, 2024	$ 70,000
December 31, 2025	282,000
December 31, 2026	289,000
December 31, 2027	296,000
December 31, 2028	245,000
Thereafter	654,000
Total minimum lease payments	1,836,000
Less imputed interest	(787,000)
Total operating lease liabilities	1,049,000	$ 1,109,000
BioLargo/ONM Lease [Member]
December 31, 2024	31,000
December 31, 2025	125,000
December 31, 2026	129,000
December 31, 2027	133,000
December 31, 2028	79,000
Thereafter	0
Total minimum lease payments	497,000
BLEST Lease [Member]
December 31, 2024	39,000
December 31, 2025	157,000
December 31, 2026	160,000
December 31, 2027	163,000
December 31, 2028	166,000
Thereafter	654,000
Total minimum lease payments	$ 1,339,000

Note 13 - Subsequent Events (De

Note 13 - Subsequent Events (Details Textual) - Subsequent Event [Member]	1 Months Ended
	Nov. 12, 2024 USD ($) $ / shares shares
Stock Issued During Period, Shares, Issued in Exchange for Reduction in Payables (in shares)	15,625
Stock Issued During Period, Shares, New Issues (in shares)	106,668
Shares Issued, Price Per Share (in dollars per share) | $ / shares	$ 6
Warrants to Refinance Equipment [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	165,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 6
Warrants Issued to Investors [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	53,337
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares	$ 7.5
Promissory Note [Member]
Debt Instrument, Face Amount | $	$ 990,000
Debt Instrument, Interest Rate During Period	15%
Debt Instrument, Term (Year)	2 years